

1 **System genetics in the rat HXB/BXH family identifies *Tti2* as a**
2 **pleiotropic quantitative trait gene for adult hippocampal**
3 **neurogenesis and serum glucose**

4
5 Anna N. Grzyb^{1,2}, Rupert W. Overall^{1,2}, Jan Silhavy³, Petr Mlejnek³, Hana Malínská⁴, Martina
6 Hüttl⁴, Irena Marková⁴, Klaus S. Fabel^{1,2}, Lu Lu⁵, Ales Stuchlik³, Robert W. Williams⁵, Michal
7 Pravenec³, Gerd Kempermann^{1,2*}

8
9 ¹ German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307
10 Dresden, Germany

11 ² CRTD – Center for Regenerative Therapies Dresden, Technische Universität Dresden,
12 Fetscherstraße 105, 01307 Dresden, Germany

13 ³ Institute of Physiology of the Czech Academy of Sciences, Videnska 1083, 14220 Prague
14 4, 142 20, Czech Republic

15 ⁴ Institute for Clinical and Experimental Medicine, Videnska 1958, 14021 Prague 4, 142 21,
16 Czech Republic

17 ⁵ Department of Genetics, Genomics and Informatics, University of Tennessee Health
18 Science Center, Memphis, TN 38163, USA

19
20 * Corresponding author

21 E-mail: gerd.kempermann@dzne.de or gerd.kempermann@tu-dresden.de

22

23 **Abstract**

24 Neurogenesis in the adult hippocampus contributes to learning and memory in the healthy
25 brain but is dysregulated in metabolic and neurodegenerative diseases. The molecular
26 relationships between neural stem cell activity, adult neurogenesis, and global metabolism
27 are largely unknown. Here we applied unbiased systems genetic methods to quantify genetic
28 covariation among adult neurogenesis and metabolic phenotypes in peripheral tissues of a
29 genetically diverse family of rat strains, derived from a cross between the spontaneously
30 hypertensive (SHR/OlaIpcv) strain and Brown Norway (BN-Lx/Cub). The HXB/BXH family is
31 a very well established model to dissect genetic variants that modulate metabolic and
32 cardiovascular disease and we have accumulated deep phenome and transcriptome data in
33 a FAIR-compliant resource for systematic and integrative analyses. Here we measured rates
34 of precursor cell proliferation, survival of new neurons, and gene expression in the
35 hippocampus of the entire HXB/BXH family, including both parents. These data were
36 combined with published metabolic phenotypes to detect a neurometabolic quantitative trait
37 locus (QTL) for serum glucose and neuronal survival. We subsequently fine-mapped a key
38 phenotype to a locus that includes the telo2-interacting protein 2 gene (*Tti2*)—a chaperone
39 that modulates the activity and stability of PIKK kinases. To validate variants in or near *Tti2*
40 as a cause for differences in neurogenesis and glucose levels, we generated a targeted
41 frameshift mutation on the SHR/OlaIpcv background. Heterozygous SHR-*Tti2*^{+/-} mutants had
42 lower rates of hippocampal neurogenesis and hallmarks of dysglycemia compared to wild-
43 type littermates. Our findings highlight *Tti2* as a causal genetic and molecular link between
44 glucose metabolism and structural brain plasticity. In humans, more than 800 genomic
45 variants are linked to *TTI2* expression, seven of which have associations to protein and blood
46 stem cell factor concentrations, blood pressure and frontotemporal dementia.

47 **Author summary**

48 Metabolic and neurological disorders are often comorbid, suggesting that biological pathways
49 which orchestrate peripheral homeostasis and the integrity of the nervous system intersect.
50 The genetic architecture behind these relationships is still poorly described, in part because
51 molecular processes in the human brain are very difficult to study. We thus used a rodent
52 genetic reference population to investigate links between adult hippocampal neurogenesis—
53 a cellular plasticity mechanism important for learning flexibility—and metabolism. We
54 measured adult neurogenesis in the family of 30 HXB/BXH rat recombinant inbred strains,
55 who are characterised by stable differences in metabolism, behaviour, and gene expression
56 levels. Because gene variants affecting distinct traits segregated into different members of
57 the family, we discovered that previously published phenotypes correlated to adult
58 neurogenesis due to shared genomic sequence. We found that expression levels of *Tti2*—a
59 part of a specialised protein chaperone complex regulating stability of PIKK kinases—were
60 concomitantly influencing adult neurogenesis and serum glucose levels. In human
61 populations hundreds of genomic variants regulate *TTI2* expression, potentially affecting
62 brain function and glucose homeostasis.

63 Introduction

64 Epidemiological studies link components of the metabolic syndrome—a complex disorder
65 characterised by the coexistence of obesity, insulin resistance, dyslipidaemia, and
66 hypertension—to cognitive impairment and dementia [1]. Defective brain function is often
67 seen as a consequence of longstanding metabolic deregulation. The full picture, however, is
68 more complex. Several human genome-wide association studies identified causal genetic
69 loci that are shared between metabolic and neurological phenotypes [2–8], suggesting some
70 degree of pleiotropy—a phenomenon whereby one gene variant affects multiple traits.
71 Pleiotropy is widespread among model organisms [9–13] and humans [2,14–17] with an
72 estimated median number of around six traits per locus [13]. Pleiotropic mutations can result
73 in genetic covariance among phenotypes [10,12]. Cognition and metabolic homeostasis are
74 both achieved through multiple elementary mechanisms at molecular, cellular, tissue, and
75 inter-organ levels, some of which might be shared. To understand the biology underlying
76 correlations between such complex functions, it is necessary to identify which exact
77 processes are simultaneously affected by shared genetic variation.

78 Adult neurogenesis in the dentate gyrus (DG) of the hippocampus is required for cognitive
79 flexibility of learning, efficient pattern separation and emotional processing in mammals [18],
80 and thus embodies a functionally relevant and readily quantifiable parameter of hippocampal
81 plasticity. In humans, according to the best available calculation, one third of dentate granule
82 cells are born during adulthood [19]. The generation of new granule neurons in the DG is a
83 complex multistep process, in the course of which neural precursor cell proliferation, as well
84 as survival, maturation, and integration of newly born postmitotic cells are under the control
85 of multiple genetic loci. Remarkably, cellular metabolism has been identified as a regulator of
86 neural stem and progenitor cell maintenance, proliferation, and differentiation [20], yet the
87 interactions of adult neurogenesis with systemic metabolism are far from being understood.
88 Given the overall significance of metabolism for brain function in health and disease, there is

89 a high likelihood that direct causal links exist between structural brain plasticity and metabolic
90 traits and states.

91 Natural genetic variation present in genetically diverse mouse populations contributes to
92 up to ten-fold differences in the net production of new neurons [21,22]—values much larger
93 than the induction achieved by environmental interventions within a single genetic
94 background. This enormous genetic potential inherent in rodent strains can be utilised to
95 dissect the molecular interaction networks not only underlying adult neurogenesis as such,
96 but also its connections with homeostatic mechanisms in peripheral tissues.

97 We thus employed a family of 30 fully inbred recombinant HXB/BXH rat strains, which
98 have been derived by reciprocal mating of a spontaneously hypertensive rat line
99 (SHR/OlaIpcv, hereafter referred to as SHR) with the normotensive BN-Lx/Cub—a Brown
100 Norway (BN) congenic rat with a mutation that causes a polydactyly-luxate phenotype
101 [23,24]. Besides hypertension, SHR manifests other hallmarks of metabolic syndrome [25–
102 27], as well as cognitive deficits [28,29], and brain morphological changes [30,31]. The
103 HXB/BXH family were developed to map quantitative trait loci (QTL) for hypertension and
104 morphological abnormalities associated with polydactyly-luxate syndrome [23,24], but they
105 are of great utility for genetic mapping of a wider spectrum of phenotypes. The HXB/BXH
106 family have become the most thoroughly characterised rat reference population within the
107 Rat Hybrid Diversity Panel [32]. Over 200 metabolic, endocrinological, behavioural and
108 developmental phenotypes, along with gene expression profiles in peripheral tissues, are
109 publicly accessible in a FAIR-compliant format at the GeneNetwork database [33,34]. The
110 stable genetic background of these recombinant inbred lines enables truly systemic
111 integration of phenotypic and omics data [32]. Accordingly, the HXB/BXH family have been
112 used to clone genes associated with several disease quantitative trait loci (QTL) and
113 discover gene regulatory networks relevant for human diseases [26,27,35–41]. The family
114 offer levels of genetic diversity comparable to human populations [42,43] and hence allow for
115 the separation of phenotypes modulated by different sets of gene variants. Correlations
116 between phenotypes, in turn, suggest shared genetic causality [10,44].

117 In the present study, we quantified adult hippocampal neurogenesis in all existing
118 HXB/BXH family members and parents. We aimed to find out the extent of genetic
119 correlations between neurogenesis and peripheral metabolism, and sought to identify
120 common loci that cause these correlations. The data reported here were submitted into
121 public databases as a part of the HXB/BXH phenome resource.

122 **Results**

123 **Adult neurogenesis in HXB/BXH strains**

124 We quantified adult hippocampal neurogenesis in DG of young male rats from all 30
125 HXB/BXH family members, as well as the parental founder strains BN and SHR. Numbers of
126 proliferating stem and progenitor cells were estimated using immunohistochemistry against
127 the Ki67 antigen (Fig. 1A, D). Dividing cells were also labelled with BrdU at 10 weeks of age
128 and surviving progeny were quantified four weeks later (Fig. 1B, E), after which time point
129 new cells are likely to persist for very long periods of time [45,46]. Newborn cells were
130 identified as neurons by double labelling with neuronal marker, NeuN (Rbfox3, Fig. 1C).
131 Among 3814 BrdU⁺ cells in 38 individuals, we detected only a single BrdU⁺/S100 β ⁺
132 astrocyte. We conclude that either astrogliogenesis is negligible in the DG of young
133 HXB/BXH rats, or S100 β (the standard marker in mice in this case) is not expressed in
134 newly-born astrocytes in these lines. Notably, over 90 % of BrdU-positive cells were neurons
135 (Fig. 1F). Hence, we used the numbers of surviving BrdU-positive cells as an approximation
136 of net neurogenesis within the HXB/BXH family. The majority of dividing cells in the DG are
137 transient amplifying progenitors, which remain tightly clustered together (Fig. 1A–A’). We
138 quantified the number of such clusters of proliferating cells, assuming that each cluster arises
139 from an activated stem cell. The number of clusters tightly correlated to counts of individual
140 cells (Pearson’s $r^2 = 0.92$; Fig. 1G). Such high correlation suggested that the numbers of
141 proliferating cells were determined by the numbers of activated stem cells rather than
142 differences in lineage progression or cell cycle dynamics in these animals, and pointed to a
143 stereotyped pattern of lineage progression.

144

145 **Fig. 1. Adult neurogenesis in the HXB/BXH family.**

146 (A) Proliferating precursor cells were stained for Ki67, a marker of actively cycling cells. (A’-
147 A’’) Proliferating cells occur in tightly packed clusters, which are likely to arise from single
148 activated stem cells. (A’) High power view of two clusters indicated by arrows in (A). (A’’) An

149 example of a single large cluster of Ki67⁺ cells. (B) New cells in the DG were identified by
150 DAB-immunostaining for BrdU 4 weeks after the last BrdU injection. (B') High power view of
151 cells indicated by an arrow. (C) BrdU-positive cells (magenta, arrowhead) were identified as
152 neurons by confocal microscopy after co-labelling with a neuronal marker, NeuN (green). (D-
153 E) The number of proliferating (D) and surviving (E) cells in the DG of HXB/BXH, BN (red)
154 and SHR (blue) strains. (F) Distribution of neuronal percentages among newborn cells
155 across HXB/BXH family confirms that more than 90% of newborn cells are neurons. Box and
156 whisker plot: centre line - median; upper and lower hinges - first and third quartiles; whiskers
157 - highest and lowest values within 1.5 times the interquartile range outside hinges; dots -
158 outlying data points. (G) Correlation between number of clusters and individual counts of
159 proliferating cells. (H-I) Quantile-quantile plots of neurogenesis traits indicate normal
160 distribution of strain means. (J) Rates of precursor cell proliferation are not predicting the
161 number of surviving cells. r , Pearson's product-moment correlation coefficient. Scale bar, 100
162 and 20 μm in A and B, 20 μm in A', A'', B'' and C.

163

164 Proliferation and survival differed between 2- and 3-fold across the strains (Fig. 1D, E)
165 and were normally distributed (Fig. 1H, I; BrdU: $W = 0.983$, $p = 0.88$; Ki67: $W = 0.976$,
166 $p = 0.67$; Shapiro-Wilk test), consistent with the multigenic regulation of adult neurogenesis.
167 Transgressive segregation was observed for both traits, indicating that genes with positive
168 effect on neurogenesis were distributed between parents. The heritability was estimated as
169 0.41 and 0.29 for survival and proliferation, respectively. Interestingly, proliferation levels did
170 not predict the rates of survival, as these measures did not correlated to each other ($r^2 =$
171 0.026; Fig. 1J). This finding implies that, under standard laboratory conditions, these two
172 aspects of neurogenesis are influenced by largely separate sets of genes.

173

174 **Shared QTL for neurogenesis and serum glucose**

175 The search for genetic associations between adult neurogenesis and physiological traits
176 was performed in several steps. First, we identified QTL for both neurogenic traits (Fig. 2A,
177 B). We detected a suggestive QTL for net neurogenesis on chromosome 16 (LOD = 3.12,
178 genome-wide corrected p value = 0.14) and a weak suggestive QTL for proliferation on
179 chromosome 17 (LOD = 2.39, p = 0.52). Second, we identified phenotypes from the
180 GeneNetwork database [34] that significantly correlated to both traits (Table 1). We then
181 used these phenotypes as covariates in conditional QTL scans to screen for potential
182 interactions at a genomic level. A substantial change in the LOD score after using another
183 phenotype as a covariate indicates that genetic variation within a QTL may have pleiotropic
184 effects on these two phenotypes [47]. Among pairs of correlating phenotypes, we detected
185 only one such association: QTL mapping for net neurogenesis revealed a LOD drop below
186 suggestive level to 0.43 after conditioning on serum glucose levels. Accordingly, an
187 overlapping significant QTL for serum glucose was found on chromosome 16 (LOD = 5.13,
188 p = 0.0065; Fig. 2C). This locus explained 37 % of the genetic variance in adult neurogenesis
189 and 61 % of the genetic variance in serum glucose. The SHR allele was associated with an
190 average decrease in BrdU cell numbers by 584 and in serum glucose by 0.656 mmol/L.

191 **Table 1. Published phenotypes correlating to adult neurogenesis in HXB/BXH family.**

Phenotype	<i>r</i>	N	<i>p</i> -value	ID
Net neurogenesis (BrdU⁺ cells)				
Glucose concentrations	0.57	24	0.0031	10003
Serum triglyceride concentrations	0.46	24	0.023	10014
Liver triglycerides	0.41	29	0.026	10119
Relative kidney weight	-0.40	28	0.034	10025
Serum chromogranin A levels	0.37	30	0.043	10132
Proliferation (Ki67⁺ cells)				
Adrenal phenyletanolamine-N-mythyltransferase	0.58	30	0.0006	10151
Adrenal dopamine	0.52	30	0.0031	10106
Adrenal epinephrine	0.47	30	0.0081	10105
Relative kidney weight	-0.45	28	0.015	10025
Insulin stimulated lipogenesis in epididymal fat	-0.44	31	0.012	10148
Adrenal chromogranin A levels	0.43	30	0.016	10133
Serum corticosterone levels after immobilization stress	-0.42	23	0.043	10064
Serum triglyceride concentrations, fed high fructose diet for 2 weeks	0.42	24	0.039	10016
Adrenal norepinephrine	0.40	30	0.029	10107
Urine calcium	0.39	28	0.041	10179
Basal lipogenesis in epididymal fat	-0.38	31	0.033	10146

192

193 All phenotypes were measured in male rats aged between 6 to 10 weeks. Details can be
 194 found in the GeneNetwork database (www.genenetwork.org). *r*, Pearson's product
 195 correlation coefficient; N, number of overlapping strains; ID, GeneNetwork identifier.

196

197 **Fig. 2. *Tti2* is a candidate gene for common net neurogenesis and serum glucose**
 198 **quantitative trait locus (QTL).**

199 (A-E) Whole-genome quantitative trait locus mapping for indicated traits. The genome-wide
 200 significant ($p < 0.05$) and suggestive ($p < 0.63$) thresholds of the logarithm of the odds (LOD)
 201 score (green and grey horizontal dashed lines, respectively) were calculated using
 202 permutations and corrected *p*-values are shown adjacent to the highest association in (A-C).
 203 QTL for net adult neurogenesis and a positively correlating phenotype, serum glucose level,
 204 have an overlapping pattern on chromosome 16. (D) An eigenvector of the two phenotypes
 205 (an *eigenphenotype*—the first principal component) was used to calculate a common
 206 confidence interval for the shared QTL (shaded areas in D and E). (E) *Tti2* gene, whose

207 genomic position is indicated by an orange triangle, has a local expression QTL within the
208 eigenphenotype QTL confidence interval on chromosome 16 in all tested tissues. For clarity,
209 in (D) and (E) only fragments of the chromosome 16 were plotted. (F) *Tti2* expression in the
210 hippocampus or tissues relevant for regulation of glucose homeostasis, as indicated in the
211 figure, is correlated to net neurogenesis and serum glucose. Colour specifies parental
212 genotypes at the marker, which had the highest LOD score association with the
213 eigenphenotype.

214 Finally, to derive a confidence interval for the joint survival-serum glucose QTL, we
215 combined the variance from both traits using their first principal component, here referred to
216 as an eigenphenotype. (Fig. 2D). The eigenphenotype QTL (LOD = 4.62, $p = 0.014$) spanned
217 4.2 Mb from genomic position 62.1 to 66.3 Mb and contained 11 protein-coding and 4 non-
218 coding RNA genes.

219 ***Tti2* is a candidate quantitative trait gene**

220 Genetic correlations between phenotypes can result from variation in shared regulatory
221 genes or from linkage disequilibrium. In linkage disequilibrium, distinct genes governing each
222 phenotype co-segregate together in the limited population of recombinant strains due to their
223 physical proximity in the genome. To distinguish these scenarios and prioritise candidate
224 genes for each phenotype, we used transcriptional profiles in tissues relevant for adult
225 neurogenesis and metabolic regulation to cross-correlate with phenotypes and genetic
226 markers. To that end, we profiled gene expression data from hippocampi of HXB/BXH and
227 parental strains using microarrays. We also used published gene expression data sets from
228 the soleus muscle, liver, perirenal fat, kidney, adrenal gland, left ventricle and aorta.
229 Expression of only one single gene, Telo2-interacting protein 2 (*Tti2*), correlated significantly
230 to both traits across all data sets (Fig. 2F). *Tti2* mRNA expression was linked to multi-tissue
231 cis-eQTL mapped within the neurogenesis-glucose QTL on chromosome 16 (Fig. 2E). We
232 thus carried out conditional mapping for neurogenesis and serum glucose using expression
233 of *Tti2* as a covariate. Substantial drop in the LOD score between unconditioned and

234 conditioned scans strongly suggests that the QTL effect is mediated by the gene
235 expression—consistent with the flow of causation from genes to phenotypes [47–49]. Using
236 *Tti2* expression in the hippocampus as a covariate decreased the LOD score for adult
237 neurogenesis by 2.34 (LOD = 0.78). To investigate the effect of *Tti2* expression in peripheral
238 tissues on serum glucose mapping, we first summarised *Tti2* expression levels in these data
239 sets as an eigengene (the first principal component). Using the *Tti2* eigengene as a covariate
240 in QTL mapping decreased the LOD score for serum glucose by 2.76 (LOD = 2.37). The
241 conditional LOD values for both phenotypes were below suggestive level. The SHR allele
242 was associated with higher levels of *Tti2* mRNA, which we verified using quantitative RT-
243 PCR in RNA isolated from the hippocampus, liver, muscle, kidney and pancreas (Table S1).

244 The allelic variation underlying a QTL can either change the expression level of a gene, or
245 the function of its product by altering its structure. We inspected the genes located within the
246 eigenphenotype QTL confidence interval for non-synonymous amino acid substitutions.
247 Interestingly, only *Tti2* carried several missense mutations, including one at a highly
248 conserved position, although none of the substitutions were predicted as damaging by
249 Polyphen or SIFT (Table S2). Together, these data support *Tti2* as a causal candidate gene
250 for the combined serum glucose and net neurogenesis QTL.

251 **Reduced *Tti2* expression impairs adult neurogenesis and metabolic homeostasis**

252 To evaluate whether expression of *Tti2* might be indeed causally linked to regulation of
253 net adult neurogenesis and serum glucose, we derived heterozygous *Tti2* knockout rats on
254 the SHR background. Using zinc finger nuclease, we introduced an 8-bp deletion in the first
255 exon of *Tti2*, which resulted in a frameshift mutation, presumably generating a non-functional
256 protein. Heterozygous male rats were compared to wild type littermates to assess
257 consequences of the reduction of available *Tti2* for adult hippocampal neurogenesis and
258 metabolism.

259 Net adult neurogenesis decreased by 21 % in the DG of 3-month-old SHR-*Tti2*^{+/-}
260 compared to their wild-type SHR littermates (Fig. 3A; see Table 2 for detailed statistical

analysis). Concomitantly, heterozygous animals exhibited extensive alterations in metabolic parameters (Fig. 3; Fig. S1; Table 2 and 3). Heterozygous knock-out of *Tti2* resulted in lower plasma glucose and insulin levels (Fig. 3B-C). SHR-*Tti2*^{+/-} rats had also elevated plasma triglycerides (TG; Fig. 3D) and non-esterified fatty acids (NEFA; Fig. 3F) compared to SHR control. Changes in plasma lipid profile were accompanied by decrease of liver TG and cholesterol content (Fig. 3G-H). However, we did not observe an effect on total or HDL-bound fraction of plasma cholesterol (Fig. 3E, Fig. S1H). In SHR-*Tti2*^{+/-} animals we observed changes in body composition and organ sizes, including lipogenic tissues: they had smaller livers and epididymal fat deposits and increased perirenal fat weights (Fig. S1B-D). On the other hand, knock-out of *Tti2* did not affect the weight of brown adipose tissue (BAT; Fig. S1E). While the heterozygous rats were slightly larger compared to the control animals (Fig. S1A), this difference was not statistically significant.

273

274 **Fig. 3. Knock-down of *Tti2* leads to decreased hippocampal neurogenesis and**
275 **impaired glucose homeostasis.**

276 (A-H) Three-months old heterozygous SHR-*Tti2*^{+/-} rats and wild type SHR-*Tti2*^{+/+} littermates
277 (denoted as SHR) were assessed for the phenotypes indicated in the figure. (I-K) Glucose
278 and lipid metabolism were measured *ex vivo* in diaphragm or epididymal adipose tissue in
279 absence (basal conditions) or presence of 250 μ U/mL insulin (stimulated condition) in the
280 incubation media. (L) Basal and adrenaline-stimulated lipolysis were measured in the
281 epididymal adipose tissue in absence or presence of 250 μ g/ml adrenaline. Number of
282 animals: (A) 18 rats of each genotype; (B-L) 8 SHR-*Tti2*^{+/-}, 6 SHR. *p* values were derived
283 from Student's *t*-test (A-H) or linear mixed effect model (I-L). Full details of statistical analysis
284 are in Tables 2 and 3. Abbreviations: NEFA, non-esterified free fatty acids; TG, triglycerides.

285 **Table 2. Statistical comparison of neurogenesis and metabolic traits between SHR-**
 286 ***Tti2*^{+/-} rats and SHR wild type littermates.**

Phenotype	Unit	SHR	SHR- <i>Tti2</i> ^{+/-}	p value
Neurogenesis	BrdU+ cells/DG	4143 ± 79	3266 ± 55	0.04 *
Body and organ weights				
Body weight	g	296.47 ± 2.62	308.41 ± 1.37	0.12
Relative weight of epid. fat	g/100 g bwt	0.69 ± 0.003	0.63 ± 0.005	0.0049 *
Relative weight of perirenal fat	g/100 g bwt	0.52 ± 0.01	0.58 ± 0.01	0.022 *
Relative weight of BAT	g/100 g bwt	0.09 ± 0.002	0.08 ± 0.002	0.71
Relative weight of liver	g/100 g bwt	3.48 ± 0.01	3.3 ± 0.01	0.0061 *
Relative weight of heart	g/100 g bwt	0.36 ± 0.003	0.35 ± 0.001	0.14
Relative weight of kidney	g/100 g bwt	0.69 ± 0.004	0.67 ± 0.002	0.028 *
Blood chemistry				
Non-fasting glucose	mmol/l	7.53 ± 0.07	6.94 ± 0.03	0.0057 *
Insulin	nmol/l	0.38 ± 0.02	0.22 ± 0.005	9.6e-5 *
Serum TG	mmol/l	0.36 ± 0.01	0.43 ± 0.01	0.048 *
Total cholesterol	mmol/l	1.13 ± 0.03	1.07 ± 0.01	0.39
HDL-C	mmol/l	1.04 ± 0.03	0.97 ± 0.01	0.27
NEFA	mmol/l	0.50 ± 0.01	0.61 ± 0.01	3.8E-4 *
Adiponectin	□g/ml	2.63 ± 0.36	2.33 ± 0.35	0.589
Leptin	ng/ml	3.20 ± 0.23	3.31 ± 0.12	0.692
Tissue composition				
TG in liver	µmol/g	6.49 ± 0.24	4.7 ± 0.12	0.016 *
Cholesterol in liver	µmol/g	10.93 ± 0.16	9.27 ± 0.07	0.0014 *
TG in heart	µmol/g	2.29 ± 0.08	0.71 ± 0.03	2.8E-6 *
TG in kidney	µmol/g	5.33 ± 0.21	5.57 ± 0.12	0.69
TG in muscle	µmol/g	1.35 ± 0.09	1.29 ± 0.06	0.80
Glucose and lipid metabolism				
Glucose oxidation in BAT	nmol glucose/g/2h	441.78 ± 19.17	386.76 ± 14.01	0.39
Basal lipogenesis in BAT	nmol glucose/g/2h	294.37 ± 11.14	262.82 ± 6.63	0.34
Basal lipogenesis in epid. fat \$	nmol glucose/g/2h	481.05 ± 18.1	417 ± 8.62	0.80
Insulin-stimulated lipogenesis in epid. fat	nmol glucose/g/2h	717.14 ± 27.08	581.48 ± 23.12	0.23
Basal lipolysis in epid. fat	µmol NEFA/g	3.01 ± 0.05	3.51 ± 0.05	0.58
Adrenaline-stimulated lipolysis in epid. fat	µmol NEFA/g	6.09 ± 0.16	5.25 ± 0.13	0.15
Basal glycogenesis in diaphragm	nmol glucose/g/2h	892.26 ± 43.12	688.17 ± 30.06	0.37
Insulin-stimulated glycogenesis in diaphragm	nmol glucose/g/2h	1554.32 ± 35.04	701.84 ± 41.14	< 1E-4 *
Glucose oxidation in diaphragm	nmol glucose/g/2h	488.38 ± 20.66	343.98 ± 8.29	0.0042 *
Oxidative stress in the liver				
SOD activity	U/mg	0.16 ± 0.004	0.12 ± 0.003	0.026 *
GPx activity	µmol GSH/min/mg	293.14 ± 6.48	234.57 ± 5.26	0.021 *

GR activity	$\mu\text{mol NADPH}/\text{min}/\text{mg}$	132.14 ± 4.51	112.57 ± 2.52	0.18
CAT activity	$\mu\text{mol H}_2\text{O}_2/\text{min}/\text{mg}$	1260 ± 45.18	1522.14 ± 50.8	0.17
GSH/GSSG		39.64 ± 1.25	25.56 ± 0.97	0.0051*
GSH	$\mu\text{mol}/\text{mg}$	75.19 ± 1.18	72.94 ± 0.61	0.49
GSSG	$\mu\text{mol}/\text{mg}$	1.96 ± 0.07	3.15 ± 0.15	0.039 *
Conjugated dienes	nM/mg	35.29 ± 0.88	42.86 ± 0.71	0.027 *
TBARS	nM/mg	1.73 ± 0.06	1.36 ± 0.05	0.095

287

288 Table reports means \pm standard errors of the mean. *p* values were derived from Student's *t*-
 289 test or post-hoc Tukey test following two-way mixed effect model with an interaction between
 290 genotype and stimulation as a fixed factor. Asterisks denote significance at $p < 0.05$.
 291 Abbreviations: BAT, brown adipose tissue; CAT, catalase; HDL-C, high-density lipoprotein
 292 bound cholesterol; epid., epididymal; GPx, glutathione peroxidase; GR, glutathione
 293 reductase; GSH, glutathione; GSSG, oxidised glutathione; NEFA, non-esterified fatty acids;
 294 SOD, superoxide dismutase; TBARS, thiobarbituric acid reactive substances; TG,
 295 triglycerides.

296

297 **Table 3. Statistical analysis of response to insulin and adrenaline stimulation in**
 298 **tissues isolated from SHR-*Tti2*^{+/-} rats and SHR wild type littermates.**

Phenotype	Term/Contrast	Statistic (d.f.)	p.value
Glycogenesis in diaphragm	Genotype	$\chi^2 (1) = 28.25$	1.1E-7 *
	Insulin	$\chi^2 (1) = 9.72$	0.0018 *
	Genotype:Insulin	$\chi^2 (1) = 11.03$	9E-4 *
	SHR:250 – SHR:0	$t(12) = 4.55$	<1E-4 *
	SHR- <i>Tti2</i> ^{+/-} :250 – SHR- <i>Tti2</i> ^{+/-} :0	$t(11) = 0.1$	1
Glucose oxidation in diaphragm	Genotype	$\chi^2 (1) = 7.82$	0.0052 *
	Insulin	$\chi^2 (1) = 1.34$	0.25
	Genotype:Insulin	$\chi^2 (1) = 3.07$	0.08
	SHR:250 – SHR:0	$t(12) = 2.08$	0.13
	SHR- <i>Tti2</i> ^{+/-} :250 – SHR- <i>Tti2</i> ^{+/-} :0	$t(12) = -0.27$	0.99
Lipogenesis in epididymal fat	Genotype	$\chi^2 (1) = 2.21$	0.14
	Insulin	$\chi^2 (1) = 34.59$	4.1E-9 *
	Genotype:Insulin	$\chi^2 (1) = 1.14$	0.29
	SHR:250 – SHR:0	$t(12) = 4.66$	<1E-4 *
	SHR- <i>Tti2</i> ^{+/-} :250 – SHR- <i>Tti2</i> ^{+/-} :0	$t(12) = 3.75$	7.7E-4 *
Lipolysis in epididymal fat	Genotype	$\chi^2 (1) = 0.35$	0.56
	Adrenaline	$\chi^2 (1) = 62.01$	3.4E-15 *
	Genotype:Adrenaline	$\chi^2 (1) = 5.08$	0.024 *
	SHR:250 – SHR:0	$t(12) = 6.86$	<1E-4 *
	SHR- <i>Tti2</i> ^{+/-} :250 – SHR- <i>Tti2</i> ^{+/-} :0	$t(12) = 4.48$	< 1E-4 *

299

300 Glucose and lipid metabolism were measured *ex vivo* in tissues isolated from SHR-*Tti2*^{+/-} rats
 301 and wild type SHR littermates under basal and induced conditions (without or with 250 μ U/ml
 302 insulin or 250 mg/ml adrenaline). The table shows results of two-way linear mixed effect
 303 models with Insulin, Genotype and Insulin:Genotype interaction or Adrenaline, Genotype and
 304 Adrenaline:Genotype as fixed effects and individual intercepts as a random effect. Statistical
 305 significance was evaluated by likelihood ratio test. Adjusted *p* values for comparisons within
 306 each genotype were obtained from *post-hoc* Tukey test for the interaction. Means and SEM
 307 for each group and the comparison between genotypes are shown in Table 2. Asterisks
 308 denote significance at *p* < 0.05; d.f., degrees of freedom.

309

310 Next, we investigated rates of glucose and lipid metabolism *ex vivo* in the skeletal muscle
311 and adipose tissues from SHR-*Tti2*^{+/-} and SHR control rats under basal conditions and upon
312 stimulation. In the diaphragm, knock-out of *Tti2* abolished stimulatory effect of insulin on both
313 glucose incorporation into glycogen, and glucose oxidation (Fig. 3I-J, see Tables 2 and 3 for
314 detailed statistical analysis). However, the basal rates of glucose oxidation and glycogenesis
315 in heterozygous rats were not significantly different from intact littermates. Similarly, basal
316 glucose oxidation in BAT was not different between genotypes (Fig. S1M). In contrast to
317 glucose utilisation in the skeletal muscle, incorporation of glucose into lipids in epididymal
318 adipose tissue was significantly stimulated by insulin in both genotypes (Fig. 3K) and we did
319 not detect differences between heterozygous and control rats in basal nor stimulated
320 condition. *De novo* lipogenesis also did not differ between SHR-*Tti2*^{+/-} and control rats in BAT
321 (Fig. S1N). Furthermore, both SHR-*Tti2*^{+/-} and SHR animals upregulated lipolysis in presence
322 of adrenaline (Fig. 3L). However, a significant interaction between genotype and adrenaline
323 stimulation suggested different response to stimulation depending on the *Tti2* expression
324 level.

325 Metabolic deregulation and dyslipidaemia are often associated with elevated oxidative
326 stress. We thus examined the hallmarks of the hepatic oxidative status. Indeed, significantly
327 upregulated conjugated dienes in livers from heterozygous rats compared to control
328 littermates (Fig. 4A) suggested increased oxidative stress. Increased oxidation was indicated
329 also by decreased ratio of reduced to oxidised glutathione (GSH/GSSG; Fig. 4G), mostly due
330 to increased concentrations of oxidised glutathione (GSSG; Fig. 4H). In contrast, the content
331 of thiobarbituric acid reactive substances (TBARS) showed a decreasing trend ($p = 0.095$;
332 Fig. 4B). The changes in lipid peroxidation were accompanied by decreased activity of the
333 antioxidant enzymes, superoxide dismutase (SOD; Fig. 4C) and glutathione peroxidase
334 (GPx; Fig. 4E). Glutathione reductase (GR; Fig. 4F) and catalase (CAT, Fig. 4D) were not
335 significantly different between SHR-*Tti2*^{+/-} and control littermates.

336

337 **Fig. 4. Knock-down of *Tti2* alters oxidative status in the liver.**

338 Livers extracts prepared from three-months old heterozygous SHR-*Tti2*^{+/-} rats (N = 7) and
339 wild type SHR littermates (N = 7) were used to measure markers of oxidative stress as
340 indicated in the figure. *p* values were derived from Student's *t*-test. Abbreviations: GSH,
341 glutathione; GSSG, oxidised glutathione; TBARS, thiobarbituric acid reactive substances.

342

343 Together, these results indicate that lowering expression of functional full-length *Tti2*
344 affected adult neurogenesis and metabolism, in particular glucose and insulin homeostasis,
345 in agreement with *Tti2* being a causal gene underlying the joint neurogenesis and serum
346 glucose QTL.

347 **Gene expression profiles indicate glucose intolerance in SHR-*Tti2*^{+/-} rats**

348 The *Tti2* protein, together with its binding partners, telomere maintenance 2 (*Telo2*) and
349 *Tti1*, form a chaperone complex that assists folding and tertiary assembly of functional
350 phosphatidylinositol 3-kinase-related kinases (PIKK): mammalian target of rapamycin
351 (mTOR), ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3 related (ATR),
352 suppressor of morphogenesis in genitalia (SMG1), transformation/transcription domain-
353 associated protein (TRRAP) and DNA-dependent protein kinase catalytic subunit (DNA-
354 PKcs) [50]. To get an insight into the molecular consequences of downregulation of *Tti2*
355 expression, we performed transcriptional profiling of the hippocampus and three tissues
356 essential for metabolic regulation in SHR-*Tti2*^{+/-} rats and their wild-type littermates. We
357 detected 326 differentially expressed transcripts in the liver, 52 in the soleus muscle, 41 in
358 the perirenal fat, and 10 in the hippocampus. In addition, the analysis confirmed reduction of
359 *Tti2* mRNA in the heterozygous rats (Table S3). We next carried out functional annotations
360 using Ingenuity Pathway Analysis (IPA), which infers shifts in activity of canonical pathways
361 and potential upstream regulators from the direction and magnitude of gene expression
362 changes using curated knowledge databases. Furthermore, IPA can link differentially
363 expressed genes to downstream outcomes.

364 We first checked whether observed gene expression changes could be connected to
365 altered activity of any of the PIKK. Among canonical pathways, IPA indicated enrichment for
366 genes associated with ATM signalling in the liver, muscle, and fat, and with mTOR signalling
367 in the muscle (Fig. S2B-D). Additionally, IPA predicted SMG1 as one of potential upstream
368 regulators in the liver and hippocampus (File S1). Nevertheless, the majority of changes in
369 gene expression were not directly connected to PIKK activity.

370 In agreement with the metabolic phenotype of SHR-*Tti2*^{+/-} rats, the transcriptional profile of
371 the liver pointed to dysglycemia, specifically to decreased glucose tolerance and increased
372 insulin resistance (Fig. 5A-B). IPA suggested four upstream regulators that could be linked to
373 glucose intolerance: interleukin 6 (IL6), tuberous sclerosis complex 2 (Tsc2), peroxisome
374 proliferator-activated receptor gamma coactivator 1-beta (Ppargc1b), and lysine (K)-specific
375 histone demethylase 1A (Kdm1a) (Fig. S3). In addition, IPA indicated inhibition of insulin
376 signalling as the most significant upstream regulator (File S2). The functional analysis also
377 predicted a broad range of other metabolic changes, for example hepatic steatosis,
378 decreased fatty acid metabolism and lipid synthesis (Fig. 5A, C; File S3). Even though only
379 few differentially expressed genes were detected in the hippocampus of SHR-*Tti2*^{+/-} rats,
380 these genes indicated decreased cellular homeostasis (Fig. 5A, D) and increased
381 apoptosis. Very strong upregulation (24-times) of sphingosine1-phosphate (S1P) receptor 3
382 (S1pr3) and downregulation of alkaline ceramidase 2 (Acer2) suggested de-regulation of
383 S1P signalling pathway in the hippocampus (Fig. S2A).

384

385 **Fig. 5. Functional analysis of gene expression changes indicates insulin resistance**
386 **and loss of cellular homeostasis in SHR-*Tti2*^{+/-} rats.**

387 Differentially expressed genes between SHR-*Tti2*^{+/-} rats and wild type SHR littermates in the
388 liver, muscle, perirenal adipose tissue and hippocampus were analysed using Ingenuity
389 Pathway Analysis (IPA). IPA predicts activation or inhibition of functions, pathological
390 processes and molecular pathways from the direction and magnitude of expression changes
391 using curated databases. (A) Graph depicts activation (positive Z-score) or inhibition

392 (negative Z-score) of top functions and diseases in each of the analysed tissues. Full list of
393 significantly affected functions can be found in File S3. (B-D) Edges in each network illustrate
394 predicted relationships between upregulated (magenta) and downregulated (green) genes
395 and downstream functions (centre nodes; orange, activating effect; blue, inhibitory effect). (E)
396 Colour key. Asterisks in network graphs denote multi-protein complexes.

397

398 **Human genomic variation links *TTI2* expression with genome-wide phenotype** 399 **associations**

400 Our results indicated that changes in expression levels of *Tti2* can affect both neural and
401 metabolic homeostases. The majority of disease-associated variants in humans are likely to
402 be involved in regulation of transcription [51,52]. Therefore, to link our findings to genomic
403 variation in the human population, we searched the human eQTL catalogue
404 (<https://www.ebi.ac.uk/eqtl/>) for variants associated with changes in the *TTI2* mRNA
405 expression. We extracted 821 variants underlying 2177 eQTL ($p < 1e-4$) in 28 different
406 tissues and cell types (File S4). Out of these, 214 variants were associated with the *TTI2*
407 eQTL in at least 3 distinct tissue types (Fig. S4). The multi-tissue eQTL are more likely to
408 represent true associations as well as being consequential for a wide range of phenotypes
409 [16,17]. We next used all *TTI2* eQTL variants to query the GWAS databases
410 (<https://www.ebi.ac.uk/gwas/>) for known phenotypic associations. We found 7 variants with
411 reported associations to protein and stem cell factor blood concentrations, blood pressure
412 and frontotemporal dementia (Table 4).

413

414 **Table 4. Human genomic variants with overlapping associations to *TTI2* expression**
 415 **and phenotypes.**

Variant ID	eQTL beta direction	eQTL data sets	Associated trait	Trait ID	GWAS p value	GWAS beta direction	Risk Frequency*
rs10094645	increase	Artery_Aorta, Muscle_Skeletal, Testis, Thyroid, Whole_Blood	blood protein measurement	EFO_0007937	4E-23	decrease	0.594
rs2732317	increase	Artery_Aorta, Testis, Thyroid, Whole_Blood	blood protein measurement	EFO_0007937	3E-77	decrease	0.612
rs2732260	increase	Monocyte	frontotemporal dementia, memory impairment	Orphanet_282 EFO_0001072	1E-6	NA	0.03
rs2732259	increase	Esophagus_Muscularis, Muscle_Skeletal, Testis, Whole_Blood	hypoxanthine measurement	EFO_0010500	7E-6	increase	0.619*
rs6996562	increase	Artery_Aorta, Testis, Whole_Blood	pulse pressure measurement	EFO_0005763	2E-10	increase	0.473
rs7845722	increase	Artery_Aorta, Muscle_Skeletal, Testis, Whole_Blood	pulse pressure measurement	EFO_0005763	1E-9	increase	0.4
rs1568119	decrease	Monocyte	stem cell factor measurement	EFO_0008291	1E-7	increase	0.08*

416

417 821 variants linked to *TTI2* eQTLs ($p < 1E-4$) were used to search human genome-wide
 418 association studies (GWAS) catalogue. *Data sets* column lists tissues and cell types in which
 419 significant eQTLs were detected for a given variant. For GWAS studies for which risk
 420 frequencies were not reported, we included variant frequencies from phase 3 1000 Genomes
 421 Project combined population (denoted with asterisks).

422

424 **Discussion**

425 In this study we used unbiased systems genetics methods to i) discover a number of
426 metabolic and endocrine genetic correlates of the two critical parameters of adult
427 hippocampal neurogenesis—precursor cell proliferation and net neurogenesis; and ii) identify
428 *Tti2* as a molecular link between brain cellular plasticity and peripheral metabolism.

429 **The HXB/BXH family is well-suited to discover genetic physiological correlates of** 430 **cognitive endophenotypes**

431 The HXB/BXH family of 30 members has only modest statistical power to detect QTL, as
432 the majority of loci have only small effects on phenotypes and variants behind a substantial
433 part of heritability fall below stringent significance levels. Nonetheless, the chief advantage of
434 recombinant inbred strains is their suitability to measure the tendency of traits to co-
435 segregate [44]. Because each inbred line can supply an indefinite number of isogenic
436 individuals, multiple phenotypes can be measured in the same genotype, the collected data
437 are cumulative and comparable across time and laboratories. Use of separate cohorts of
438 animals to assess different phenotypes precludes intra-individual correlations and ensures
439 that any associations between traits are due to shared genetic variation. Genetic
440 correlations, therefore, may suggest the presence of allelic variants with pleiotropic effects on
441 correlating phenotypes. Here we showed that, under basic laboratory conditions, precursor
442 cell proliferation and the final outcome of adult neurogenesis—numbers of surviving
443 neurons—are under the control of largely distinct sets of genes. Accordingly, each of these
444 traits correlated to non-overlapping collections of metabolic and endocrine parameters.
445 Because adult neurogenesis—although a complex process in itself—represents one specific
446 aspect of brain plasticity, these correlations advance our understanding of interactions
447 between global metabolic features and cognition. Here we proceeded to dissect in-depth the
448 correlation between serum glucose and net neurogenesis, which could both be mapped to a
449 common overlapping QTL. The majority of discovered correlations, however, could not be
450 explained by such a strong genetic association, in agreement with the polygenic nature of

451 quantitative traits. Other methods, such as gene co-expression analyses, have the potential
452 to integrate available data and elucidate mechanisms underlying remaining relationships
453 [32].

454 ***Tti2* as a pleiotropic gene regulating net neurogenesis and metabolic homeostasis**

455 Using transcriptional profiles from peripheral tissues and the hippocampus as intermediate
456 phenotypes between complex physiological outcomes and genomic variation we were able to
457 narrow down the 'serum glucose-neurogenesis' QTL interval to the *Tti2* candidate gene. *Tti2*,
458 together with its binding partners, *Tti1* and telomere maintenance 2 (*Telo2*) protein, form the
459 Triple T (TTT) complex [53], which associates with a number of molecular chaperones,
460 including Hsp90, Hsp70, Hsp40, and the R2TP/prefoldin-like complex [54,55]. TTT binds to
461 nascent peptides of PI3K-related protein kinases (PIKK) and thereby acts as a specialised
462 chaperone and a critical regulator of PIKK abundance in mammalian and yeast cells [53,55–
463 58]. In mammals, the PIKK family consists of ATM, ATR, mTOR, TRAPP, SMG1, and DNA-
464 PKcs. These proteins play strategic roles in multiple cellular functions, such as genome
465 stability, DNA repair, regulation of gene and protein expression, nonsense-mediated RNA
466 decay, cell growth and cell cycle progression, and regulation of responses to nutrient
467 availability [59–62]. All PIKK are also an important part of stress responses [63].

468 In our present study, we generated a heterozygous SHR-*Tti2*^{+/-} line carrying a frame-shift
469 mutation in the N-terminal domain of *Tti2*. Mutational screens in yeast produced viable cells
470 only when truncations were located at the very end of the C-terminus of *Tti2* [64], hence we
471 predicted that this modification results in a non-functional protein. Our aim was to mirror the
472 eQTL effect and reduce the amount of available *Tti2* rather than remove it completely. The
473 SHR background had been chosen because the SHR allele is associated with higher *Tti2*
474 expression. The mutation halved the *Tti2* mRNA content in heterozygous rats compared to
475 the wild-type littermates, as established by RNA sequencing. Although antibodies
476 recognising rodent *Tti2* were not available, experiments in yeast have suggested that the *Tti2*
477 protein abundance is directly correlated to mRNA expression [53]. SHR-*Tti2*^{+/-} rats had

478 similar body weights, gross morphology and general cage behaviour as the wild-type
479 littermates. However, reducing *Tti2* expression to 50% led to a reduction of the number of
480 new neurons in the DG, a concomitant lowering of serum glucose and insulin concentrations,
481 and to hallmarks of insulin resistance in skeletal muscles. Metabolic alterations in SHR-*Tti2*^{+/-}
482 rats went beyond glucose homeostasis: we also observed changes in lipid metabolism and
483 elevated oxidative stress in the liver. Together, these findings support *Tti2* as a causal gene
484 within the joint 'serum glucose-neurogenesis' QTL.

485 Expression of *Tti2* correlated negatively to adult neurogenesis and serum glucose
486 concentrations in the HXB/BXH family, yet in the SHR rats with only one functional copy of
487 the *Tti2* gene we saw a further decrease of each trait value. This disparity would imply that
488 the SHR allele is associated with decrease of the *Tti2* protein function despite higher *Tti2*
489 mRNA abundance. The SHR allele carries six amino-acid substitutions, including Glu247Asp
490 within the highly conserved *Tti2* family super-helical central domain (conservation score 1.0;
491 see Supplementary Table 1) and Lys198Glu at a moderately conserved residue (score 0.57)
492 in the N-terminal portion of the protein. Although all substitutions were scored as benign by
493 prediction algorithms SIFT and PolyPhen, it cannot be excluded that they have an impact on
494 protein stability or interactions with any of the binding partners. Higher mRNA expression
495 could evolve independently or as a compensation of reduced function. For example, in the
496 duplicated maize genome, the number of copies of genes encoding TTT complex members
497 and PIKK have all reverted to one, suggesting evolutionary pressure to maintain gene
498 dosage balance [65].

499 Transcriptome profiling of SHR-*Tti2*^{+/-} rats revealed extensive gene expression changes in
500 the liver, and to a lesser degree in the skeletal muscle, perirenal fat and hippocampus
501 compared to SHR wild type littermates. Liver, together with skeletal muscle and adipose
502 tissue are decisive organs in maintenance of glucose homeostasis and hence development
503 of insulin resistance [66]. Functional analysis of differentially expressed genes in the liver
504 identified networks of genes and potential regulators whose activation and inhibition could
505 explain insulin resistance and dysglycemia in the heterozygous animals. We also recorded

506 significant upregulation of *Insr* in the muscle, which IPA interpreted as consistent with
507 hypoglycaemia and insulin resistant diabetes (File S3).

508 We also used IPA to predict which upstream regulators could be activated or inhibited in a
509 manner consistent with observed gene expression changes. The vast majority of differentially
510 expressed genes were not linked to PIKK activity. Thus far only PIKK peptides were
511 identified as clients of the TTT complex despite attempts to capture other target proteins [64].
512 Therefore it is unlikely that another, yet unknown, pathway contributes to the observed
513 phenotypes. Depletion of *Tti2* destabilises all PIKK proteins and impairs nuclear localisation
514 of ATM, ATR and TRRAP, but does not affect their mRNA abundance [53,64].
515 Notwithstanding the lack of direct evidence, reduction of *Tti2* expression in SHR-*Tti2*^{+/-} rats
516 may destabilise the TTT complex and consequently impair signalling of PIKK. It has been
517 reported that reduced PIKK signalling due to tissue-specific targeting of selected genes in the
518 mouse led to impaired adipogenesis (reduced fat deposits), insulin resistance with lower
519 insulin-stimulated glucose transport, reduced antilipolytic effects of insulin (increased NEFA
520 levels), and ectopic fat accumulation [67–71]. These results are similar to metabolic
521 disturbances observed in SHR-*Tti2*^{+/-} rats suggesting involvement of the same molecular
522 pathways. Our data also do not allow differentiating whether all or only some of the PIKK are
523 compromised in the SHR-*Tti2*^{+/-} rats. Destabilisation of the TTT complex has strongest
524 effects on ATM and ATR protein levels and to a lesser extent other PIKK [53,58,64,72].
525 Interestingly, in SHR-*Tti2*^{+/-} rats IPA detected enrichment of differentially expressed genes
526 related to ATM signalling in the liver, muscle and fat and mTOR signalling in the muscle.
527 While these results do not imply that other PIKK were not affected, ATM might be the most
528 sensitive to *Tti2* downregulation also in rats used in our study.

529 Pleiotropy occurs when a single genomic variation, or more broadly a change in a function
530 of a single gene, has multiple consequences at the phenotypic level [9]. Because metabolic
531 diseases can, to some extent, be modified by lifestyle interventions in order to prevent or
532 dampen cognitive decline, but genes cannot, it is clinically crucial to understand which
533 correlations between metabolic and cognitive phenotypes arise from genetic predisposition

534 due to pleiotropic genes. Because we used targeted mutagenesis at the *Tti2* locus rather
535 than tissue specific approaches to confirm association with target phenotypes, we cannot
536 exclude that *Tti2* affects neurogenesis through circulating metabolites or hormones.
537 Correlations between traits in the absence of genetic variation indicate indirect effects [10].
538 Hippocampal plasticity and neurogenesis are intricately related to nutrient availability and
539 insulin and insulin-like growth factor 1 (IGF1) signalling [73–76]. Glucose is the primary
540 energy source for the nervous system. Hyperglycemia and insulin resistance are detrimental
541 to the brain and negatively influence adult hippocampal neurogenesis [77–80]. In addition,
542 caloric restriction, which lowers plasma insulin and glucose levels, resulted in increased
543 survival of new neurons and higher net neurogenesis [81]. These associations hint that, as
544 such, the lower serum glucose measured in SHR-*Tti2*^{+/-} rats may not necessarily lead to
545 lower neuronal survival. In the HXB/BXH family, neurogenesis correlated positively to serum
546 insulin (Pearson's $r = 0.35$, $p = 0.09$). However, we did not detect any consistent associations
547 with measures of insulin resistance, suggesting that peripheral insulin resistance is also
548 unlikely a sole cause of neurogenesis impairment in SHR-*Tti2*^{+/-} rats. Furthermore,
549 transcriptional profiling of the hippocampus from heterozygous animals did not indicate brain
550 insulin resistance. Metabolic tissues in heterozygous rats also manifested deregulated lipid
551 metabolism. Higher levels of circulating triglycerides and free fatty acids could further
552 contribute to disrupted glucose metabolism and neurogenesis. For example, high fat diets,
553 which increase circulating plasma lipids and lipid peroxidation, have been documented as
554 detrimental to neurogenesis and cognition [82,83].

555 The support in favour of direct effects of *Tti2* reduction on neurogenesis comes from the
556 severe neural deficits in individuals carrying loss-of-function mutations in *TTI2* in the absence
557 of serious metabolic insufficiencies. In humans, homozygous and compound heterozygous
558 loss-of-function mutations in *TTI2* cause microcephaly, severe intellectual disability,
559 dysmorphic facial features, short stature, speech and movement disorders, and skeletal
560 deformations [72,84–86]. Similar abnormalities were observed in children carrying *TELO2*
561 mutations [87,88]. Particularly, failures of DNA repair pathways downstream of the TTT

562 complex have detrimental effects on development and maintenance of the central nervous
563 system. Recessive mutations in ATM cause ataxia telangiectasia, a disease characterised by
564 progressive neuronal degeneration [89,90]; while loss of ATR leads to Seckel syndrome
565 characterised by postnatal dwarfism, microcephaly, intrauterine growth defects, and mental
566 retardation [91]. ATM, ATR and DNA-PKcs are essential to preserving the genome integrity
567 during replication [92] and thus their function is particularly important in dividing precursor
568 cells in the course of neurogenesis [93], also in the adult hippocampus [94]. Knock-out of
569 ATM or ATR in mice has detrimental effects on brain development, with pronounced loss of
570 hippocampal neurons [95]. ATM-deficient mice have abnormally increased rates of
571 proliferation with concomitantly lowered survival of new neurons [94]. In human neural stem
572 cells, ATM suppresses excessive retrotransposition [96], the process which contributes to
573 neural diversity and plasticity during hippocampus development, and then in the adult stem
574 cells [97].

575 mTOR also plays multiple roles in the development and function of the brain [98],
576 including maintenance of neural progenitor cell pools. During embryonic development,
577 conditional knockout of mTOR in neural stem cells dramatically reduced their proliferation
578 thereby reducing production of postmitotic neurons and brain size [99]. Similarly, inhibition of
579 mTORC1 signalling in the neural stem cells in the neonatal subventricular zone (SVZ) of the
580 lateral ventricle, which also harbours a population of neural stem cells that persist throughout
581 life, reduced generation of transient amplifying precursor cells and thus decreased the
582 abundance of their differentiated progeny [100]. In addition, transient systemic inhibition of
583 the mTOR pathway by rapamycin in early postnatal life resulted in abnormal proliferation,
584 reduced progenitor cell numbers, and eventually decreased the volume of the adult dentate
585 gyrus [101].

586 ATM and mTOR are both downstream targets of insulin and IGF1 signalling [89]. Insulin
587 and IGF1 provide trophic signals that can both stimulate and inhibit proliferation and survival
588 of adult precursor cells *in vivo* [74,102–107]. Insulin is also expressed directly in neuronal
589 progenitors [108]. The massive upregulation of S1pr3 and downregulation of Acer2 in the

590 hippocampus of SHR-*Tti2*^{+/-} rats suggested changes in the sphingosine-1-phosphate (S1P)
591 signalling pathway, which is implicated in the control of cell death and survival, as well as
592 synaptic plasticity via interactions with multiple cellular signalling cascades [109–112].
593 Interestingly, S1pr3 potentiates IGF1 signalling [113], and cross-links with the mTOR-AKT
594 nutrient sensing pathway [114]. Although our analysis of differentially expressed genes did
595 not suggest changes in PIKK activity in the hippocampus of heterozygous animals, the
596 precursor cells and immature neurons are only a minor fraction of the entire hippocampus
597 and therefore we might not have captured genes affected specifically in these cells. For
598 example, Ka and colleagues [99] found that in the developing cerebral cortex mTOR
599 signalling was detected mostly in the radial neural stem cells, the principal precursor cells of
600 the developing central nervous system, with very low activity in the postmitotic neuronal
601 layers. In the early postnatal and adult SVZ, mTOR activity was also concentrated in actively
602 proliferating transient amplifying progenitor cells [100,115]. All told, the interwoven
603 relationships between peripheral metabolism, insulin and PIKK signalling pathways point to
604 complex responses to intracellular deficits in PIKK and extracellular signals in the brain of
605 SHR-*Tti2*^{+/-} rats, and lend support for truly pleiotropic roles of *Tti2* in the regulation of glucose
606 homeostasis and structural brain plasticity. Future development of tissue- and cell-specific
607 conditional knockouts shall help to decipher the consequences of *Tti2* depletion for these
608 functions independently of each other.

609 **Limitations**

610 In our study we used only male rats. This decision was dictated by compatibility with
611 existing data, as the vast majority of published HXB/BXH phenotypes were measured in
612 young male rats to avoid inter-individual variation due to oestrous cycle. Further experiments
613 will show whether any of the identified associations interacts with sex.

614 **Conclusion**

615 Understanding of the molecular events by which a genomic variation leads to
616 physiological consequences for the organism across many functions provides a foundation
617 for effective precision medicine. Our study exemplifies the power of rodent genetic reference
618 populations not only to identify associations between phenotypes that are difficult or even
619 impossible to assess in humans, but also to give insights into the cell biology behind these
620 associations. Our experiments showed that manipulating the abundance of a single
621 component of the protein folding machinery had relatively subtle yet significant effects on a
622 broad range of phenotypes. Mining human data sets revealed more than 800 genomic
623 variants that are linked to *TTI2* expression, seven of which refer to associations with protein
624 and blood stem cell factor concentrations, blood pressure, and frontotemporal dementia.
625 Given the dose-dependent effects of *Tti2* on adult hippocampal neurogenesis and glucose
626 homeostasis, we speculate that human variants that affect *TTI2* expression or function may
627 also have quantitative effects on these phenotypes.

628 **Acknowledgments**

629 The authors would like to thank Karel Vales, Michaela Radostna, Hana Brozka, Jan-Hendrik
630 Claasen, Perla Leal-Galicia, Tara L. Walker, and Sara Zocher for assistance with perfusions;
631 Anna Rumiantseva for help with histological staining; Vladimir Landa for microinjecting
632 fertilised ova with the ZFN construct; Olena Oliyarnyk for oxidative stress analysis; Edwin
633 Cuppen, Marieke Simonis, Kathrin Saar, and Oliver Hummel for SHR genomic variants and
634 genotype information.

635 **Funding**

636 This work was supported by DFG (KE 615/9-1) (ANG, GK), Energi (ANG, GK) and basic
637 TUD and DZNE institutional funding (ANG, RWO, KSF, GK). MP and HM were supported by
638 the Ministry of Health of the Czech Republic under the conceptual development of research

639 organizations program (Institute for Clinical and Experimental Medicine – IKEM, IN 00023001
640 (HM) and by the Academic Premium (Praemium academiae) (AP1502) (MP); AS was
641 supported by Czech Health Research Council (AZV) grant 17-30833A and Czech Science
642 Foundation (GACR) projects 19-03016S and 20-00939S.
643

644 **Materials and Methods**

645 **Animals**

646 Brown Norway BN-Lx/Cub, spontaneously hypertensive SHR/OlaIpcv (referred to as BN
647 and SHR, respectively) and 30 HXB/BXH recombinant inbred strains, as well as SHR-*Tti2*^{+/-}
648 knockout heterozygous rats used in the current study were housed in an air-conditioned
649 animal facility at the Institute of Physiology, Czech Academy of Sciences. HXB/BXH strains
650 are inbred for more than 80 generations. Animals were maintained on a 12 h light/dark cycle
651 in the standard laboratory cages provided with standard laboratory chow and water *ad*
652 *libitum*. To assess survival of new-born cells in the dentate gyrus, 10-week-old animals were
653 given 3 daily intraperitoneal injections of 50 mg/kg bromodeoxyuridine (BrdU; Sigma) and
654 perfused 28 days later. We studied 5–9 male rats from each strain derived from at least 3
655 independent litters (total 243 rats). To isolate tissues for RNA and protein isolation, rats were
656 anaesthetised with ketamine and decapitated. Tissues were placed in RNA later (microarray)
657 or snap frozen in liquid nitrogen. For the microarray analysis, one male and one female 10-
658 week-old rat from each parental and HXB/BXH strains were used (total 64 rats). Biochemical,
659 metabolic and hemodynamic phenotypes were assessed in 3-month-old non-fasted male
660 SHR-*Tti2*^{+/-} rats and their wild-type littermates (N = 8 per strain). All experiments were
661 performed in agreement with the Animal Protection Law of the Czech Republic and were
662 approved by the Ethics Committee of the Institute of Physiology, Czech Academy of
663 Sciences, Prague (Permit number: 66/2014).

664 **Generation of *Tti2* knockout SHR rats.**

665 *Tti2* knockout rats were generated by microinjecting fertilized ova of SHR rats with the
666 ZFN (Zinc Finger Nuclease) construct from Sigma-Aldrich. The construct was designed to
667 target the first exon using the following sequence of ZFN binding (capital letters) and cutting
668 site (small letters): TCTGACCCGGATCCAAGCaccaagGGTGGGTGGCAGGGC. DNA
669 samples isolated from 452 rats born after microinjection with ZFN construct were amplified

670 using primers flanking the target sequence: ZFN F: 5'-TACACTGTGATTGGCTGGGA-3' and
671 ZFN R: 5'-GGCGCAGTGGAGTGATC-3'. Altogether 4 positive animals were detected. An
672 SHR-*Tti2*^{tm1/lpcv} line no.14 (referred to as SHR-*Tti2*^{+/-}) with an 8 bp deletion
673 (NM_001013883.1(*Tti2*):c.243_250delCGAGATCC; on the protein level:
674 NP_001013905.1:p.Glu82Glyfs) has been selected for further analyses. The heterozygous
675 founder was crossed with SHR and F1 rats were intercrossed. SHR-*Tti2*^{+/-} heterozygotes
676 were selected for breeding and phenotyping while their wild type littermates were used as
677 controls.

678 **Histology**

679 Histology was carried out using standard procedures [45]. Rats were deeply
680 anaesthetised with a mixture of ketamine/xylazine and intracardially perfused with 0.9%
681 NaCl, followed by ice-cold 4 % paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB),
682 pH 7.4. The brains were removed, post-fixed overnight in 4 % PFA and equilibrated in 30 %
683 w/v sucrose in 0.1 M phosphate buffer. 40 µm frozen coronal sections were cut on a sliding
684 microtome (Leica) and stored in a cryo-protective solution (25 % ethylene glycol, 25 %
685 glycerol in 0.1 M PB) at -20 °C.

686 For immunohistochemistry, every sixth section was washed in Tris-buffered saline (TBS)
687 and pretreated in 3 % H₂O₂ and 10 % methanol in TBS for 15 min. After several washes in
688 TBS and NaCl, DNA was denatured with 2.5 M HCl for 30 min at 37 °C. Multiple washes in
689 phosphate-buffered saline (PBS) were performed between each subsequent step. The
690 sections were incubated in a blocking solution containing 10 % donkey serum and 0.3 %
691 Triton-X100 in PBS for 1 h and then with primary antibodies (rat anti-BrdU, 1:500, OBT0030,
692 AbD Serotec; or rabbit anti-Ki67, 1:500, NCL-Ki67p, Novocastra) diluted in the blocking
693 solution for 48 – 72 h at 4 °C. Sections were incubated for 2.5 h with biotinylated secondary
694 antibodies (1:500, Jackson ImmunoResearch) diluted in the blocking solution containing 3 %
695 donkey serum. Immunocomplexes were detected using the Vectastain Elite ABC kit (Vector
696 Laboratories) and 0.02 % diaminobenzidine (D5905, Sigma) enhanced with NiCl₂. After

697 mounting in 0.1 M PB onto gelatine-coated glass slides, the sections were air dried, cleared
698 in the alcohol gradient series, and coverslipped with Entellan New (Merck).

699 Cells were quantified using a simplified optical fractionator method as discussed before
700 [Kempermann 2003 PMID: 12466205]. BrdU positive cells were quantified along the rostro-
701 caudal axis in the granule cell layer (GCL) and subgranular zone (SGZ) defined as a two-cell
702 wide band below the GCL. Ki67 cells were quantified in the three-cell wide zone below the
703 GCL and in the inner third of the GCL. Clusters of cells were defined as at least three cells
704 not further apart than two-cell diameter. The cells in the uppermost focal plane were ignored
705 to avoid oversampling errors. The counts from left and right sides of the DG in each sample
706 were averaged and multiplied by 6 (section sampling interval) to obtain total numbers of
707 newborn (BrdU) or proliferating (Ki67) cells in per dentate gyrus.

708 To assess the identity of BrdU-positive cells and estimate the range of neuronal and
709 astrocyte survival across the HXB/BXH family, sections from three randomly selected
710 individuals from each parental strain and one from each HXB/BXH member were processed
711 for fluorescent staining with BrdU, NeuN and S100 β . Every twelfth section was washed twice
712 in NaCl, pretreated in 2 M HCl for 30 min at 37 $^{\circ}$ C and washed in PBS. After blocking,
713 sections were incubated for 48 h at 4 $^{\circ}$ C with primary antibodies (rat anti-BrdU, 1:500, OBT
714 Serotec; mouse anti-NeuN, 1:200, MAB377, Millipore; rabbit anti-S100 β , 1:2000, Ab41548,
715 Abcam) diluted in the blocking solution. After washing in PBS, sections were incubated for
716 4 h with secondary antibodies (anti-rat Cy3, anti-mouse DyLight 488, anti-rabbit Cy5, 1:500,
717 Jackson Immunoresearch) diluted in the blocking solution, washed in PBS and mounted onto
718 glass slides using fluorescence mounting medium Aqua-Poly/Mount (Polysciences). 100
719 randomly selected BrdU-positive cells from each animal along the rostro-caudal axis of the
720 DG were imaged at 400 \times magnification with spectral confocal microscope (TCS SP2, Leica)
721 and examined for NeuN and S100 β immunoreactivity.

722 **Microarray analysis**

723 Hippocampi were dissected from brains stored in RNA later and RNA was isolated using
724 RNA STAT-60 kit (Tel-Test Inc). RNA was purified using standard sodium acetate-ethanol
725 precipitation method. RNA purity and concentration was evaluated using 260/280 nm
726 absorbance ratio and the quality was checked using Agilent Bioanalyzer 2100 prior to
727 hybridisation. Samples were hybridised onto GeneChip Rat Exon 1.0 ST microarrays
728 (Affymetrix) using manufacturers protocols.

729 Along with the hippocampus gene expression data, we analysed published data sets from
730 parental and 29 recombinant inbred strains from adrenal gland, liver, skeletal muscle,
731 perirenal fat, kidney, aorta and ventricle [37,38,40]. These data sets consisted of microarray
732 analysis on Affymetrix Rat230_2 (muscle, liver, aorta and ventricle) and RAE230A (adrenal
733 gland, fat and kidney) chips. Unprocessed microarray expression data were retrieved from
734 ArrayExpress, (www.ebi.ac.uk/arrayexpress; adrenal gland, E-TABM-457; liver, E-MTAB-
735 323; muscle, E-TABM-458; fat and kidney, E-AFMX-7; aorta, E-MTAB-322; left ventricle, E-
736 MIMR-222).

737 Probes from each data set were assembled into probesets mapped to Ensemble gene
738 identifiers from Rnor_5.0 rat genome release using Version 10 custom cell definition files
739 from the Brain Array (University of Michigan) website [116]. Probes that mapped to regions
740 containing insertions, deletions or single nucleotide polymorphisms in the SHR/Ola or BN-
741 Lx/Cub strains compared to the reference genome [43] were removed prior the analysis to
742 avoid spurious linkage due to differential hybridisation. Probesets which after filtering
743 contained less than 3 probes were removed. Gene expression summaries were derived
744 using robust multichip average (RMA) algorithm [117] in the R Affy package [118].

745 **Heritability**

746 In repeated sampling of isogenic individuals, the variance observed within the genotype
747 can be attributed to environmental influences, whereas differences between strains are
748 primarily due to differences in genotypes. Thus, we defined narrow sense heritability as the

749 intraclass correlation coefficient obtained from a mixed linear model employing restricted
750 maximum likelihood approach using function *lmer* from lme4 R package [119,120].

751 **QTL mapping**

752 Phenotype QTL were calculated using strain means for surviving (BrdU⁺) and proliferating
753 (Ki67⁺) cells in the DG as well as for phenotypes correlating to neurogenesis traits.
754 Expression QTL (eQTL) were calculated for all genes in each data set. Marker regression
755 against SNP-based genotype markers mapped to Rnor_5.0 genome assembly with 2049
756 unique strain distribution patterns in 29 HXB/BXH strains [121] was performed using the
757 QTLReaper program [122], which reports likelihood ratio statistic (LRS) score at each
758 marker. LRS was converted to logarithm of odds ratio (LOD) by dividing by 4.61, where LOD
759 $\approx -\log_{10}(p)$. Empirical genome-wide significance of linkage was determined by a permutation
760 test as previously described [37]. Genome wide significance was defined as the 95th
761 percentile of the maximum LOD score and less stringent suggestive threshold as the 37th
762 percentile, which on average yields one false positive per genome scan [123,124]. The 95 %
763 confidence intervals for QTL were calculated in R/qtl using Bayesian method [125]. Traits
764 with overlapping QTL were summarised as their first principal component, an
765 eigenphenotype (adult neurogenesis and serum glucose) or eigengene (*Tti2* expression),
766 using WGCNA R package [126]. eQTL were defined as local when position of a QTL
767 mapped within 10 Mb from the physical location of the gene [37]. Conditional genome scans
768 were carried out in R/qtl as described previously [47–49] to establish relationships between
769 genomic loci, gene expression and phenotypes using function *scanone* with parameter
770 *addcovar*. The gene was considered causal when the LOD score of the phenotype QTL fell
771 below suggestive level after conditioning on its expression. Analysis of mutations of
772 candidate genes was performed using tools in Rat Genome Database [127]. All genomic
773 positions were mapped to Rnor_5.0 genome assembly.

774 **RNA isolation and quantitative PCR**

775 RNA was isolated using RNeasy Mini Kit (Qiagen) following manufacturer's instructions.
776 Genomic DNA was removed by on-column DNase digestion. Frozen tissues were
777 homogenised in QIAzol with TissueRuptor (Qiagen). cDNA was synthesised with SuperScript
778 II reverse transcriptase (Invitrogen) using oligo(dT) primers and 1 µg of total RNA.
779 Quantitative PCR was performed using SYBR Green PCR kit (Qiagen) on cDNA
780 corresponding to 25 ng of total RNA using the following conditions: 95 °C for 15 min, and 40
781 cycles at 94 °C for 15 s, 60 °C for 30 s and 72 °C for 30 s. Gene-specific primer pairs were
782 designed using Primer3 software [128]. Dissociation analysis from 55 °C to 90 °C of the end
783 product was performed to ensure specificity. Cycle of threshold (CT) values were normalised
784 to the GAPDH reference to calculate the relative level of gene expression on the log₂ scale
785 (Δ CT). Mean Δ CT values from BN rats were then subtracted from each sample Δ CT to obtain
786 $\Delta\Delta$ CT values.

787 **RNA sequencing and analysis**

788 RNA was isolated as described above from the frozen hippocampus, liver, soleus muscle
789 and perirenal adipose tissue samples isolated from SHR-Tti2^{+/-} rats and wild-type SHR-Tti2^{+/+}
790 littermates. RNA integrity was confirmed using BioAnalyzer (Agilent Technologies,
791 Germany). Sequencing libraries were prepared using NEBNext® Ultra™ II Directional RNA
792 Library Prep Kit for Illumina® from 300 ng of total RNA, with mRNA enrichment by poly-dT
793 pull down using the NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB) according to
794 the manufacturer's instructions. Samples were then directly subjected to the workflow for
795 strand-specific RNA-Seq library preparation (Ultra II Directional RNA Library Prep, NEB). For
796 ligation custom adaptors were used (Adaptor-Oligo 1: 5'-ACA CTC TTT CCC TAC ACG ACG
797 CTC TTC CGA TCT-3', Adaptor-Oligo 2: 5'-P-GAT CGG AAG AGC ACA CGT CTG AAC
798 TCC AGT CAC-3'). After ligation, adaptors were depleted by an XP bead purification
799 (Beckman Coulter) adding the beads solution in a ratio of 1:0.9. Dual indexing was done
800 during the following PCR enrichment (12 cycles, 65 °C) using custom amplification primers

801 carrying the same sequence for i7 and i5 index (Primer 1: AAT GAT ACG GCG ACC ACC
802 GAG ATC TAC AC NNNNNNNN ACA TCT TTC CCT ACA CGA CGC TCT TCC GAT CT,
803 Primer 2: CAA GCA GAA GAC GGC ATA CGA GAT NNNNNNNN GTG ACT GGA GTT CAG
804 ACG TGT GCT CTT CCG ATC T). After two more XP bead purifications (1:0.9), libraries
805 were quantified using the Fragment Analyzer (Agilent). For Illumina flowcell production,
806 samples were equimolarly pooled and sequenced 75bp single-end on multiple Illumina
807 NextSeq 500 flowcells, aiming for approximately 30 million sequencing reads per sample.

808 Expression levels of individual transcripts were estimated by kallisto (ver. 0.46.1) [129]
809 using Ensembl cDNA database (release 97) [130] as a reference. The software was
810 executed with sequence-based bias correction, 100 bootstrap samples, an average fragment
811 length of 200 bp and standard deviation set to 20. Differential expression analysis was
812 carried out using an R package sleuth (ver. 0.30.0) [131]. A single outlier hippocampus
813 sample was identified by examining a principal component projection and removed from
814 further analysis. Samples obtained from each tissue were used to fit independent statistical
815 models, with genotype as a single covariate, using 5 or 4 replicates per genotype. Statistical
816 significances of changes in transcript abundances were computed using a Wald test. A 10 %
817 FDR (false discovery rate) cut-off and an absolute value of fold change of 1.5 were used to
818 identify differentially expressed genes. Functional enrichment analysis was performed with
819 Ingenuity Pathway Analysis software (IPA; Qiagen) at default settings [132].

820 **Basal and insulin stimulated glycogen synthesis in skeletal muscle.**

821 For measurement of insulin stimulated incorporation of glucose into glycogen,
822 diaphragmatic muscles were incubated for 2 h in 95% O₂ + 5% CO₂ in Krebs-Ringer
823 bicarbonate buffer, pH 7.4, containing 0.1 μ Ci/ml of ¹⁴C-U glucose, 5 mmol/L of unlabelled
824 glucose, and 2.5 mg/ml of bovine serum albumin (Armour, Fraction V), with or without 250
825 μ U/ml insulin. Glycogen was extracted, and basal and insulin stimulated incorporation of
826 glucose into glycogen was determined.

827 **Glucose utilization in isolated epididymal adipose tissue and brown adipose tissue.**

828 Distal parts of epididymal adipose tissue or interscapular brown adipose tissue were
829 rapidly dissected and incubated for 2 hours in Krebs-Ringer bicarbonate buffer with 5 mmol/L
830 glucose, 0.1 μ Ci 14 C-U-glucose/mL (UVVR, Prague, Czech Republic) and 2% bovine serum
831 albumin, gaseous phase 95% O₂ and 5% CO₂ in the presence (250 μ U/mL) or absence of
832 insulin in incubation media. All incubations were performed at 37 °C in sealed vials in a
833 shaking water bath. Then we estimated incorporation of 14 C-glucose into neutral lipids.
834 Briefly, adipose tissue was removed from incubation medium, rinsed in saline, and
835 immediately put into chloroform. The pieces of tissue were dissolved using a Teflon pestle
836 homogenizer, methanol was added (chloroform:methanol 2:1), and lipids were extracted at
837 4 °C overnight. The remaining tissue was removed, KH₂PO₄ was added and a clear extract
838 was taken for further analysis. An aliquot was evaporated, reconstituted in scintillation liquid,
839 and the radioactivity measured by scintillation counting. Incremental glucose utilization was
840 calculated as the difference between the insulin stimulated and basal incorporation of
841 glucose into neutral lipids.

842 **Lipolysis in isolated epididymal adipose tissue.**

843 For measurement of basal and adrenaline stimulated lipolysis, the distal parts of
844 epididymal adipose tissue were incubated in Krebs-Ringer phosphate buffer containing 3 %
845 bovine serum albumin (Armour, Fraction V) at 37 °C, pH 7.4 with or without adrenaline (0.25
846 μ g/ml). The tissue was incubated for 2 hours and the concentrations of NEFA and glycerol in
847 the medium were determined.

848 **Tissue triglyceride and cholesterol measurements.**

849 For determination of triglycerides in liver, gastrocnemius muscle, kidney, and heart,
850 tissues were powdered under liquid N₂ and extracted for 16 hours in chloroform:methanol,
851 after which 2 % KH₂PO₄ was added and the solution was centrifuged. The organic phase
852 was removed and evaporated under N₂. The resulting pellet was dissolved in isopropyl

853 alcohol, and triglyceride and cholesterol concentrations were determined by enzymatic assay
854 (Pliva-Lachema, Brno, Czech Republic).

855 **Biochemical analyses.**

856 Blood glucose levels were measured by the glucose oxidase assay (Pliva-Lachema, Brno,
857 Czech Republic) using tail vein blood drawn into 5 % trichloroacetic acid and promptly
858 centrifuged. NEFA levels were determined using an acyl-CoA oxidase-based colorimetric kit
859 (Roche Diagnostics GmbH, Mannheim, Germany). Serum triglyceride and cholesterol
860 concentrations were measured by standard enzymatic methods (Pliva-Lachema, Brno,
861 Czech Republic). Glycerol was determined using an analytical kit from Sigma. Serum insulin
862 concentrations were determined using a rat insulin ELISA kit (Mercodia, Uppsala, Sweden).

863 **Parameters of oxidative stress.**

864 Activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and
865 glutathione reductase (GR) were analysed using Cayman Chemicals assay kits (MI, USA)
866 according to manufacturer's instructions. Catalase (CAT) activity measurement was based
867 on the ability of H₂O₂ to produce with ammonium molybdate a colour complex detected
868 spectrophotometrically. The level of reduced glutathione (GSH) was determined in the
869 reaction of SH-groups using Ellman reagent. The level of reduced (GSH) and oxidized
870 (GSSG) form of glutathione was determined by high-performance liquid chromatography
871 method with fluorescent detection according to HPLC diagnostic kit (Chromsystems, Munich,
872 Germany). Lipoperoxidation products were assessed by the levels of thiobarbituric acid
873 reactive substances (TBARS) determined by assaying the reaction with thiobarbituric acid.
874 The levels of conjugated dienes were analysed by extraction in the media
875 (heptane:isopropanol = 2:1) and measured spectrophotometrically in heptane's layer.

876 **Statistical analysis**

877 Statistical analyses were performed in R [133]. Normality of distribution of strain means for
878 neurogenesis phenotypes was checked using Shapiro-Wilk test. Differences between groups

879 were tested using Student's *t*-test or ANOVA followed by Tukey or Dunnett's post hoc test.
880 Responses to insulin were analysed with a two-way linear mixed effect models using the
881 lme4 R package [120]. Genotype, insulin treatment and interaction between genotype and
882 treatment were used as fixed effects and individual intercepts were used as a random effect.
883 Significance of main terms was evaluated by likelihood ratio test using function *Anova* from
884 the car package [134], followed by Tukey post hoc test using multcomp package [135].
885 Values are represented as means +/- standard error of the mean. Plots were generated
886 using the ggplot2 package [136].

887 **Data**

888 Neurogenesis data was deposited in the HXB/BXH Published Phenotypes Database at
889 the GeneNetwork (www.genenetwork.org) under Record IDs: 10193 (BrdU⁺ cells), 10194
890 (Ki67⁺ cells), 10195 (clusters of Ki67⁺ cells). Hippocampal gene expression dataset was
891 deposited at GeneNetwork under GN Accession GN231. RNA sequencing of SHR and SHR-
892 *Tti2*^{+/-} rats was deposited to Gene Ontology Omnibus under the accession number
893 GSE160361.
894

895 References

- 896 1. Panza F, Solfrizzi V, Logroscino G, Maggi S, Santamato A, Seripa D, et al. Current
897 epidemiological approaches to the metabolic-cognitive syndrome. *Journal of*
898 *Alzheimer's Disease*. IOS Press; 2012. doi:10.3233/JAD-2012-111496
- 899 2. Watanabe K, Stringer S, Frei O, Umičević Mirkov M, de Leeuw C, Polderman TJC, et
900 al. A global overview of pleiotropy and genetic architecture in complex traits. *Nat*
901 *Genet*. 2019;51: 1339–1348. doi:10.1038/s41588-019-0481-0
- 902 3. Lumsden AL, Mulugeta A, Zhou A, Hyppönen E. Apolipoprotein E (APOE) genotype-
903 associated disease risks: a phenome-wide, registry-based, case-control study utilising
904 the UK Biobank. *EBioMedicine*. 2020;59. doi:10.1016/j.ebiom.2020.102954
- 905 4. Nikpay M, Mohammadzadeh S. Phenome-wide screening for traits causally
906 associated with the risk of coronary artery disease. *J Hum Genet*. 2020;65: 371–380.
907 doi:10.1038/s10038-019-0716-z
- 908 5. Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC,
909 et al. Improved detection of common variants associated with schizophrenia by
910 leveraging pleiotropy with cardiovascular-disease risk factors. *Am J Hum Genet*.
911 2013;92: 197–209. doi:10.1016/j.ajhg.2013.01.001
- 912 6. Zhang T, Goodman M, Zhu F, Healy B, Carruthers R, Chitnis T, et al. Phenome-wide
913 examination of comorbidity burden and multiple sclerosis disease severity. *Neurol*
914 *Neuroimmunol neuroinflammation*. 2020;7. doi:10.1212/NXI.0000000000000864
- 915 7. Thomassen JQ, Tolstrup JS, Benn M, Frikke-Schmidt R. Type-2 diabetes and risk of
916 dementia: Observational and Mendelian randomisation studies in 1 million individuals.
917 *Epidemiol Psychiatr Sci*. 2020;29. doi:10.1017/S2045796020000347
- 918 8. Mollon J, Curran JE, Mathias SR, Knowles EEM, Carlisle P, Fox PT, et al.
919 Neurocognitive impairment in type 2 diabetes: evidence for shared genetic aetiology.
920 *Diabetologia*. 2020;63: 977–986. doi:10.1007/s00125-020-05101-y
- 921 9. Stearns FW. One hundred years of pleiotropy: A retrospective. *Genetics*. *Genetics*;
922 2010. pp. 767–773. doi:10.1534/genetics.110.122549
- 923 10. Geiler-Samerotte KA, Li S, Lazaris C, Taylor A, Ziv N, Ramjeawan C, et al. Extent and
924 context dependence of pleiotropy revealed by high-throughput single-cell phenotyping.
925 *PLoS Biol*. 2020;18. doi:10.1371/journal.pbio.3000836
- 926 11. White JK, Gerdin AK, Karp NA, Ryder E, Buljan M, Bussell JN, et al. XGenome-wide
927 generation and systematic phenotyping of knockout mice reveals new roles for many
928 genes. *Cell*. 2013;154: 452. doi:10.1016/j.cell.2013.06.022
- 929 12. McGuigan K, Collet JM, McGraw EA, Ye YH, Allen SL, Chenoweth SF, et al. The
930 nature and extent of mutational pleiotropy in gene expression of male *Drosophila*
931 *serrata*. *Genetics*. 2014;196: 911–921. doi:10.1534/genetics.114.161232
- 932 13. Wagner GP, Zhang J. The pleiotropic structure of the genotype-phenotype map: The
933 evolvability of complex organisms. *Nature Reviews Genetics*. *Nat Rev Genet*; 2011.
934 pp. 204–213. doi:10.1038/nrg2949
- 935 14. Sivakumaran S, Agakov F, Theodoratou E, Prendergast JG, Zgaga L, Manolio T, et al.
936 Abundant pleiotropy in human complex diseases and traits. *Am J Hum Genet*.
937 2011;89: 607–618. doi:10.1016/j.ajhg.2011.10.004
- 938 15. Pickrell JK, Berisa T, Liu JZ, Ségurel L, Tung JY, Hinds DA. Detection and
939 interpretation of shared genetic influences on 42 human traits. *Nat Genet*. 2016;48:
940 709–717. doi:10.1038/ng.3570
- 941 16. Shikov AE, Skitchenko RK, Predeus A V., Barbitoff YA. Phenome-wide functional
942 dissection of pleiotropic effects highlights key molecular pathways for human complex
943 traits. *Sci Rep*. 2020;10: 1–10. doi:10.1038/s41598-020-58040-4
- 944 17. Jordan DM, Verbanck M, Do R. HOPS: A quantitative score reveals pervasive
945 horizontal pleiotropy in human genetic variation is driven by extreme polygenicity of
946 human traits and diseases. *Genome Biol*. 2019;20. doi:10.1186/s13059-019-1844-7
- 947 18. Toda T, Gage FH. Review: adult neurogenesis contributes to hippocampal plasticity.

- 948 Cell and Tissue Research. Springer Verlag; 2018. pp. 693–709. doi:10.1007/s00441-
949 017-2735-4
- 950 19. Spalding KL, Bergmann O, Alkass K, Bernard S, Salehpour M, Huttner HB, et al.
951 X Dynamics of hippocampal neurogenesis in adult humans. *Cell*. 2013;153: 1219.
952 doi:10.1016/j.cell.2013.05.002
- 953 20. Knobloch M, Jessberger S. Metabolism and neurogenesis. *Current Opinion in*
954 *Neurobiology*. Elsevier Ltd; 2017. pp. 45–52. doi:10.1016/j.conb.2016.11.006
- 955 21. Kempermann G, Chesler EJ, Lu L, Williams RW, Gage FH. Natural variation and
956 genetic covariance in adult hippocampal neurogenesis. *Proc Natl Acad Sci U S A*.
957 2006;103: 780–785. doi:10.1073/pnas.0510291103
- 958 22. Kempermann G, Kuhn HG, Gage FH. Genetic influence on neurogenesis in the
959 dentate gyrus of adult mice. *Proc Natl Acad Sci U S A*. 1997;94: 10409–10414.
960 doi:10.1073/pnas.94.19.10409
- 961 23. Printz MP, Jirout M, Jaworski R, Alemayehu A, Kren V. Invited review: HXB/BXH rat
962 recombinant inbred strain platform: A newly enhanced tool for cardiovascular,
963 behavioral, and developmental genetics and genomics. *Journal of Applied Physiology*.
964 American Physiological Society; 2003. pp. 2510–2522.
965 doi:10.1152/jappphysiol.00064.2003
- 966 24. Liska F, Peterkova R, Peterka M, Landa V, Zödek V, Mlejnek P, et al. Targeting of
967 the Plzf gene in the rat by transcription activator-like Effector nuclease results in
968 caudal regression syndrome in spontaneously hypertensive rats. *PLoS One*. 2016;11.
969 doi:10.1371/journal.pone.0164206
- 970 25. Mondon CE, Reaven GM. Evidence of abnormalities of insulin metabolism in rats with
971 spontaneous hypertension. *Metabolism*. 1988;37: 303–305. doi:10.1016/0026-
972 0495(88)90127-8
- 973 26. Pravenec M, Zídek V, Landa V, Šimáková M, Mlejnek P, Kazdová L, et al. Genetic
974 Analysis of “Metabolic Syndrome” in the Spontaneously Hypertensive Rat. *Physiol*
975 *Res*. 2004;53: 15–22. Available: <http://www.biomed.cas.cz/physiolres>
- 976 27. Pravenec M. Use of rat genomics for investigating the metabolic syndrome. *Methods*
977 *Mol Biol*. 2010;597: 415–426. doi:10.1007/978-1-60327-389-3_28
- 978 28. Terry A V., Hernandez CM, Buccafusco JJ, Gattu M. Deficits in spatial learning and
979 nicotinic-acetylcholine receptors in older, spontaneously hypertensive rats.
980 *Neuroscience*. 2000;101: 357–368. doi:10.1016/S0306-4522(00)00377-8
- 981 29. Grünblatt E, Bartl J, Luhos D-I, Knezovic A, Trkulja V, Riederer P, et al.
982 Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied
983 by brain insulin receptor dysfunction. *J Mol Psychiatry*. 2015;3. doi:10.1186/s40303-
984 015-0012-6
- 985 30. Sabbatini M, Stocchi P, Vitaioli L, Amenta F. The hippocampus in spontaneously
986 hypertensive rats: A quantitative microanatomical study. *Neuroscience*. 2000;100:
987 251–258. doi:10.1016/S0306-4522(00)00297-9
- 988 31. Mignini F, Vitaioli L, Sabbatini M, Tomassoni D, Amenta F. The cerebral cortex of
989 spontaneously hypertensive rats: A quantitative microanatomical study. *Clinical and*
990 *Experimental Hypertension*. Clin Exp Hypertens; 2004. pp. 287–303.
991 doi:10.1081/CEH-120034135
- 992 32. Tabakoff B, Smith H, Vanderlinden LA, Hoffman PL, Saba LM. Networking in Biology:
993 The Hybrid Rat Diversity Panel. *Methods in Molecular Biology*. Humana Press Inc.;
994 2019. pp. 213–231. doi:10.1007/978-1-4939-9581-3_10
- 995 33. Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al.
996 Comment: The FAIR Guiding Principles for scientific data management and
997 stewardship. *Sci Data*. 2016;3: 1–9. doi:10.1038/sdata.2016.18
- 998 34. Mulligan MK, Mozhui K, Prins P, Williams RW. Genenetwork: A toolbox for systems
999 genetics. *Methods in Molecular Biology*. Humana Press Inc.; 2017. pp. 75–120.
1000 doi:10.1007/978-1-4939-6427-7_4
- 1001 35. Aitman TJ, Critser JK, Cuppen E, Dominiczak A, Fernandez-Suarez XM, Flint J, et al.
1002 Progress and prospects in rat genetics: A community view. *Nature Genetics*. Nat

- 1003 Genet; 2008. pp. 516–522. doi:10.1038/ng.147
- 1004 36. Morrissey C, Grieve IC, Heinig M, Atanur S, Petretto E, Pravenec M, et al. Integrated
1005 genomic approaches to identification of candidate genes underlying metabolic and
1006 cardiovascular phenotypes in the spontaneously hypertensive rat. *Physiol Genomics*.
1007 2011;43: 1207–1218. doi:10.1152/physiolgenomics.00210.2010
- 1008 37. Hubner N, Wallace CA, Zimdahl H, Petretto E, Schulz H, Maciver F, et al. Integrated
1009 transcriptional profiling and linkage analysis for identification of genes underlying
1010 disease. *Nat Genet*. 2005;37: 243–253. doi:10.1038/ng1522
- 1011 38. Petretto E, Mangion J, Dickens NJ, Cook SA, Kumaran MK, Lu H, et al. Heritability
1012 and tissue specificity of expression quantitative trait loci. *PLoS Genet*. 2006;2: 1625–
1013 1633. doi:10.1371/journal.pgen.0020172
- 1014 39. Adriaens ME, Lodder EM, Moreno-Moral A, Silhavý J, Heinig M, Glinge C, et al.
1015 Systems genetics approaches in rat identify novel genes and gene networks
1016 associated with cardiac conduction. *J Am Heart Assoc*. 2018;7.
1017 doi:10.1161/JAHA.118.009243
- 1018 40. Heinig M, Petretto E, Wallace C, Bottolo L, Rotival M, Lu H, et al. A trans-acting locus
1019 regulates an anti-viral expression network and type 1 diabetes risk. *Nature*. 2010;467:
1020 460–464. doi:10.1038/nature09386
- 1021 41. Pravenec M, Churchill PC, Churchill MC, Viklicky O, Kazdova L, Aitman TJ, et al.
1022 Identification of renal Cd36 as a determinant of blood pressure and risk for
1023 hypertension. *Nat Genet*. 2008;40: 952–954. doi:10.1038/ng.164
- 1024 42. Atanur SS, Birol I, Guryev V, Hirst M, Hummel O, Morrissey C, et al. The genome
1025 sequence of the spontaneously hypertensive rat: Analysis and functional significance.
1026 *Genome Res*. 2010;20: 791–803. doi:10.1101/gr.103499.109
- 1027 43. Simonis M, Atanur SS, Linsen S, Guryev V, Ruzius FP, Game L, et al. Genetic basis
1028 of transcriptome differences between the founder strains of the rat HXB/BXH
1029 recombinant inbred panel. *Genome Biol*. 2012;13. doi:10.1186/gb-2012-13-4-r31
- 1030 44. Nadeau JH, Burrage LC, Restivo J, Pao YH, Churchill G, Hoit BD. Pleiotropy,
1031 homeostasis, and functional networks based on assays of cardiovascular traits in
1032 genetically randomized populations. *Genome Res*. 2003;13: 2082–2091.
1033 doi:10.1101/gr.1186603
- 1034 45. Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH. Early determination
1035 and long-term persistence of adult-generated new neurons in the hippocampus of
1036 mice. *Development*. 2003. pp. 391–399. doi:10.1242/dev.00203
- 1037 46. Zocher S, Schilling S, Grzyb AN, Adusumilli VS, Lopes JB, Günther S, et al. Early-life
1038 environmental enrichment generates persistent individualized behavior in mice. *Sci*
1039 *Adv*. 2020;6. doi:10.1126/sciadv.abb1478
- 1040 47. Li R, Tsaih SW, Shockley K, Stylianou IM, Wergedal J, Paigen B, et al. Structural
1041 model analysis of multiple quantitative traits. *PLoS Genet*. 2006;2: 1046–1057.
1042 doi:10.1371/journal.pgen.0020114
- 1043 48. Leduc MS, Blair RH, Verdugo RA, Tsaih SW, Walsh K, Churchill GA, et al. Using
1044 bioinformatics and systems genetics to dissect HDL-cholesterol genetics in an
1045 MRL/MpJ x SM/J intercross. *J Lipid Res*. 2012;53: 1163–1175.
1046 doi:10.1194/jlr.M025833
- 1047 49. Leduc MS, Hageman RS, Verdugo RA, Tsaih SW, Walsh K, Churchill GA, et al.
1048 Integration of QTL and bioinformatic tools to identify candidate genes for triglycerides
1049 in mice. *J Lipid Res*. 2011;52: 1672–1682. doi:10.1194/jlr.M011130
- 1050 50. Sugimoto K. Branching the Tel2 pathway for exact fit on phosphatidylinositol 3-kinase-
1051 related kinases. *Current Genetics*. Springer Verlag; 2018. pp. 965–970.
1052 doi:10.1007/s00294-018-0817-9
- 1053 51. Ardlie KG, DeLuca DS, Segrè A V., Sullivan TJ, Young TR, Gelfand ET, et al. The
1054 Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in
1055 humans. *Science (80-)*. 2015;348: 648–660. doi:10.1126/science.1262110
- 1056 52. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-Associated
1057 SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS.

- 1058 Gibson G, editor. PLoS Genet. 2010;6: e1000888. doi:10.1371/journal.pgen.1000888
- 1059 53. Hurov KE, Cotta-Ramusino C, Elledge SJ. A genetic screen identifies the Triple T
- 1060 complex required for DNA damage signaling and ATM and ATR stability. *Genes Dev.*
- 1061 2010;24: 1939–1950. doi:10.1101/gad.1934210
- 1062 54. Hořejší Z, Takai H, Adelman CA, Collis SJ, Flynn H, Maslen S, et al. CK2 phospho-
- 1063 dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1
- 1064 stability. *Mol Cell.* 2010;39: 839–850. doi:10.1016/j.molcel.2010.08.037
- 1065 55. Takai H, Xie Y, De Lange T, Pavletich NP. Tel2 structure and function in the Hsp90-
- 1066 dependent maturation of mTOR and ATR complexes. *Genes Dev.* 2010;24: 2019–
- 1067 2030. doi:10.1101/gad.1956410
- 1068 56. Stirling PC, Bloom MS, Solanki-Patil T, Smith S, Sipahimalani P, Li Z, et al. The
- 1069 complete spectrum of yeast chromosome instability genes identifies candidate cin
- 1070 cancer genes and functional roles for astra complex components. *PLoS Genet.*
- 1071 2011;7. doi:10.1371/journal.pgen.1002057
- 1072 57. Takai H, Wang RC, Takai KK, Yang H, de Lange T. Tel2 Regulates the Stability of
- 1073 PI3K-Related Protein Kinases. *Cell.* 2007;131: 1248–1259.
- 1074 doi:10.1016/j.cell.2007.10.052
- 1075 58. Kaizuka T, Hara T, Oshiro N, Kikkawa U, Yonezawa K, Takehana K, et al. Tti1 and
- 1076 Tel2 are critical factors in mammalian target of rapamycin complex assembly. *J Biol*
- 1077 *Chem.* 2010;285: 20109–20116. doi:10.1074/jbc.M110.121699
- 1078 59. Yamashita A. Role of SMG-1-mediated Upf1 phosphorylation in mammalian
- 1079 nonsense-mediated mRNA decay. *Genes to Cells. Genes Cells*; 2013. pp. 161–175.
- 1080 doi:10.1111/gtc.12033
- 1081 60. Cimprich KA, Cortez D. ATR: An essential regulator of genome integrity. *Nature*
- 1082 *Reviews Molecular Cell Biology. Nat Rev Mol Cell Biol*; 2008. pp. 616–627.
- 1083 doi:10.1038/nrm2450
- 1084 61. Shimobayashi M, Hall MN. Making new contacts: The mTOR network in metabolism
- 1085 and signalling crosstalk. *Nat Rev Mol Cell Biol.* 2014;15: 155–162.
- 1086 doi:10.1038/nrm3757
- 1087 62. Murr R, Vaissière T, Sawan C, Shukla V, Herceg Z. Orchestration of chromatin-based
- 1088 processes: Mind the TRRAP. *Oncogene. Oncogene*; 2007. pp. 5358–5372.
- 1089 doi:10.1038/sj.onc.1210605
- 1090 63. Abraham RT. PI 3-kinase related kinases: “Big” players in stress-induced signaling
- 1091 pathways. *DNA Repair. Elsevier*; 2004. pp. 883–887.
- 1092 doi:10.1016/j.dnarep.2004.04.002
- 1093 64. Hoffman KS, Duennwald ML, Karagiannis J, Genereaux J, McCarton AS, Brandl CJ.
- 1094 *Saccharomyces cerevisiae* Tti2 regulates PIKK proteins and stress response. *G3*
- 1095 *Genes, Genomes, Genet.* 2016;6: 1649–1659. doi:10.1534/g3.116.029520
- 1096 65. Garcia N, Messing J. TTT and PIKK complex genes reverted to single copy following
- 1097 polyploidization and retain function despite massive retrotransposition in maize. *Front*
- 1098 *Plant Sci.* 2017;8. doi:10.3389/fpls.2017.01723
- 1099 66. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance.
- 1100 *Physiological Reviews. American Physiological Society*; 2018. pp. 2133–2223.
- 1101 doi:10.1152/physrev.00063.2017
- 1102 67. Shan T, Zhang P, Jiang Q, Xiong Y, Wang Y, Kuang S. Adipocyte-specific deletion of
- 1103 mTOR inhibits adipose tissue development and causes insulin resistance in mice.
- 1104 *Diabetologia.* 2016;59: 1995–2004. doi:10.1007/s00125-016-4006-4
- 1105 68. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JC. Muscle-
- 1106 Specific Deletion of Rictor Impairs Insulin-Stimulated Glucose Transport and
- 1107 Enhances Basal Glycogen Synthase Activity. *Mol Cell Biol.* 2008;28: 61–70.
- 1108 doi:10.1128/mcb.01405-07
- 1109 69. Kumar A, Lawrence JC, Jung DY, Ko HJ, Keller SR, Kim JK, et al. Fat cell-specific
- 1110 ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and
- 1111 lipid metabolism. *Diabetes.* 2010;59: 1397–1406. doi:10.2337/db09-1061
- 1112 70. Takagi M, Uno H, Nishi R, Sugimoto M, Hasegawa S, Piao J, et al. ATM Regulates

- 1113 Adipocyte Differentiation and Contributes to Glucose Homeostasis. *Cell Rep.* 2015;10:
1114 957–967. doi:10.1016/j.celrep.2015.01.027
- 1115 71. Mao Z, Zhang W. Role of mTOR in glucose and lipid metabolism. *International Journal*
1116 *of Molecular Sciences.* MDPI AG; 2018. doi:10.3390/ijms19072043
- 1117 72. Langouët M, Saadi A, Rieunier G, Moutton S, Siquier-Pernet K, Fernet M, et al.
1118 Mutation in TTI2 reveals a role for triple T complex in human brain development. *Hum*
1119 *Mutat.* 2013;34: 1472–1476. doi:10.1002/humu.22399
- 1120 73. Mainardi M, Fusco S, Grassi C. Modulation of hippocampal neural plasticity by
1121 glucose-related signaling. *Neural Plasticity.* Hindawi Publishing Corporation; 2015.
1122 doi:10.1155/2015/657928
- 1123 74. Fernandez AM, Torres-Alemán I. The many faces of insulin-like peptide signalling in
1124 the brain. *Nature Reviews Neuroscience.* *Nat Rev Neurosci*; 2012. pp. 225–239.
1125 doi:10.1038/nrn3209
- 1126 75. van Praag X, Fleshner M, Schwartz MW, Mattson MP. Exercise, energy intake,
1127 glucose homeostasis, and the brain. *J Neurosci.* 2014;34: 15139–15149.
1128 doi:10.1523/JNEUROSCI.2814-14.2014
- 1129 76. Rafalski VA, Brunet A. Energy metabolism in adult neural stem cell fate. *Progress in*
1130 *Neurobiology.* *Prog Neurobiol*; 2011. pp. 182–203.
1131 doi:10.1016/j.pneurobio.2010.10.007
- 1132 77. Marissal-Arvy N, Campas MN, Semont A, Ducroix-Crepy C, Beauvieux MC, Brossaud
1133 J, et al. Insulin treatment partially prevents cognitive and hippocampal alterations as
1134 well as glucocorticoid dysregulation in early-onset insulin-deficient diabetic rats.
1135 *Psychoneuroendocrinology.* 2018;93: 72–81. doi:10.1016/j.psyneuen.2018.04.016
- 1136 78. Sun P, Knezovic A, Parlak M, Cuber J, Karabeg M, Deckert J, et al. Long-Term Effects
1137 of Intracerebroventricular Streptozotocin Treatment on Adult Neurogenesis in the Rat
1138 Hippocampus. *Curr Alzheimer Res.* 2015;12: 772–784.
1139 doi:10.2174/1567205012666150710112147
- 1140 79. Stranahan AM, Arumugam T V., Cutler RG, Lee K, Egan JM, Mattson MP. Diabetes
1141 impairs hippocampal function through glucocorticoid-mediated effects on new and
1142 mature neurons. *Nat Neurosci.* 2008;11: 309–317. doi:10.1038/nn2055
- 1143 80. Zhang WJ, Tan YF, Yue JTY, Vranic M, Wojtowicz JM. Impairment of hippocampal
1144 neurogenesis in streptozotocin-treated diabetic rats. *Acta Neurol Scand.* 2008;117:
1145 205–210. doi:10.1111/j.1600-0404.2007.00928.x
- 1146 81. Lee J, Seroogy KB, Mattson MP. Dietary restriction enhances neurotrophin expression
1147 and neurogenesis in the hippocampus of adult mice. *J Neurochem.* 2002;80: 539–547.
1148 doi:10.1046/j.0022-3042.2001.00747.x
- 1149 82. Park HR, Park M, Choi J, Park KY, Chung HY, Lee J. A high-fat diet impairs
1150 neurogenesis: Involvement of lipid peroxidation and brain-derived neurotrophic factor.
1151 *Neurosci Lett.* 2010;482: 235–239. doi:10.1016/j.neulet.2010.07.046
- 1152 83. Klein C, Jonas W, Iggena D, Empl L, Rivalan M, Wiedmer P, et al. Exercise prevents
1153 high-fat diet-induced impairment of flexible memory expression in the water maze and
1154 modulates adult hippocampal neurogenesis in mice. *Neurobiol Learn Mem.* 2016;131:
1155 26–35. doi:10.1016/j.nlm.2016.03.002
- 1156 84. Ziegler A, Bader P, McWalter K, Douglas G, Houdayer C, Bris C, et al. Confirmation
1157 that variants in TTI2 are responsible for autosomal recessive intellectual disability. *Clin*
1158 *Genet.* 2019;96: 354–358. doi:10.1111/cge.13603
- 1159 85. Wang R, Han S, Liu H, Khan A, Xiaerhati H, Yu X, et al. Novel compound
1160 heterozygous mutations in *tti2* cause syndromic intellectual disability in a chinese
1161 family. *Front Genet.* 2019;10. doi:10.3389/fgene.2019.01060
- 1162 86. Picher-Martel V, Labrie Y, Rivest S, Lacey B, Chrestian N. Whole-exome sequencing
1163 identifies homozygous mutation in TTI2 in a child with primary microcephaly: A case
1164 report. *BMC Neurol.* 2020;20. doi:10.1186/s12883-020-01643-1
- 1165 87. You J, Sobreira NL, Gable DL, Jurgens J, Grange DK, Belnap N, et al. A Syndromic
1166 Intellectual Disability Disorder Caused by Variants in *TELO2*, a Gene Encoding a
1167 Component of the TTT Complex. *Am J Hum Genet.* 2016;98: 909–918.

- 1168 doi:10.1016/j.ajhg.2016.03.014
1169 88. Moosa S, Altmüller J, Lyngbye T, Christensen R, Li Y, Nürnberg P, et al. Novel
1170 compound heterozygous mutations in TELO2 in a patient with severe expression of
1171 You-Hoover-Fong syndrome. *Mol Genet Genomic Med.* 2017;5: 580–584.
1172 doi:10.1002/mgg3.287
1173 89. Choy KR, Watters DJ. Neurodegeneration in ataxia-telangiectasia: Multiple roles of
1174 ATM kinase in cellular homeostasis. *Developmental Dynamics.* John Wiley and Sons
1175 Inc.; 2018. pp. 33–46. doi:10.1002/dvdy.24522
1176 90. Shiloh Y, Ziv Y. The ATM protein kinase: Regulating the cellular response to genotoxic
1177 stress, and more. *Nature Reviews Molecular Cell Biology.* *Nat Rev Mol Cell Biol*; 2013.
1178 pp. 197–210. doi:10.1038/nrm3546
1179 91. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation
1180 affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in
1181 Seckel syndrome. *Nat Genet.* 2003;33: 497–501. doi:10.1038/ng1129
1182 92. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. *Nature*
1183 *Reviews Molecular Cell Biology.* Nature Publishing Group; 2008. pp. 297–308.
1184 doi:10.1038/nrm2351
1185 93. Enriquez-Rios V, Dumitrache LC, Downing SM, Li Y, Brown EJ, Russell HR, et al.
1186 DNA-PKcs, ATM, and ATR interplay maintains genome integrity during neurogenesis.
1187 *J Neurosci.* 2017;37: 893–905. doi:10.1523/JNEUROSCI.4213-15.2016
1188 94. Allen DM, Van Praag H, Ray J, Weaver Z, Winrow CJ, Carter TA, et al. Ataxia
1189 telangiectasia mutated is essential during adult neurogenesis. *Genes Dev.* 2001;15:
1190 554–566. doi:10.1101/gad.869001
1191 95. Lee Y, Shull ERP, Frappart PO, Katyal S, Enriquez-Rios V, Zhao J, et al. ATR
1192 maintains select progenitors during nervous system development. *EMBO J.* 2012;31:
1193 1177–1189. doi:10.1038/emboj.2011.493
1194 96. Coufal NG, Garcia-Perez JL, Peng GE, Marchetto MCN, Muotri AR, Mu Y, et al. Ataxia
1195 telangiectasia mutated (ATM) modulates long interspersed element-1 (L1)
1196 retrotransposition in human neural stem cells. *Proc Natl Acad Sci U S A.* 2011;108:
1197 20382–20387. doi:10.1073/pnas.1100273108
1198 97. Singer T, McConnell MJ, Marchetto MCN, Coufal NG, Gage FH. LINE-1
1199 retrotransposons: Mediators of somatic variation in neuronal genomes? *Trends*
1200 *Neurosci.* 2010;33: 345–354. doi:10.1016/j.tins.2010.04.001
1201 98. Garza-Lombó C, Gonsebatt ME. Mammalian target of rapamycin: Its role in early
1202 neural development and in adult and aged brain function. *Frontiers in Cellular*
1203 *Neuroscience.* *Frontiers Media S.A.*; 2016. doi:10.3389/fncel.2016.00157
1204 99. Ka M, Condorelli G, Woodgett JR, Kim WY. mTOR regulates brain morphogenesis by
1205 mediating GSK3 signaling. *Dev.* 2014;141: 4076–4086. doi:10.1242/dev.108282
1206 100. Hartman NW, Lin T V., Zhang L, Paquelet GE, Feliciano DM, Bordey A. MTORC1
1207 Targets the Translational Repressor 4E-BP2, but Not S6 Kinase 1/2, to Regulate
1208 Neural Stem Cell Self-Renewal InVivo. *Cell Rep.* 2013;5: 433–444.
1209 doi:10.1016/j.celrep.2013.09.017
1210 101. Raman L, Kong X, Kernie SG. Pharmacological inhibition of the mTOR pathway
1211 impairs hippocampal development in mice. *Neurosci Lett.* 2013;541: 9–14.
1212 doi:10.1016/j.neulet.2013.01.045
1213 102. Åberg MAI, Åberg ND, Palmer TD, Alborn AM, Carlsson-Skwirut C, Bang P, et al. IGF-
1214 I has a direct proliferative effect in adult hippocampal progenitor cells. *Mol Cell*
1215 *Neurosci.* 2003;24: 23–40. doi:10.1016/S1044-7431(03)00082-4
1216 103. Trejo JL, Carro E, Torres-Alemán I. Circulating insulin-like growth factor I mediates
1217 exercise-induced increases in the number of new neurons in the adult hippocampus. *J*
1218 *Neurosci.* 2001;21: 1628–1634. doi:10.1523/jneurosci.21-05-01628.2001
1219 104. Lichtenwalner RJ, Forbes ME, Bennett SA, Lynch CD, Sonntag WE, Riddle DR.
1220 Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-
1221 related decline in hippocampal neurogenesis. *Neuroscience.* 2001;107: 603–613.
1222 doi:10.1016/S0306-4522(01)00378-5

- 1223 105. Cheng CM, Cohen M, Tseng V, Bondy CA. Endogenous IGF1 enhances cell survival
1224 in the postnatal dentate gyrus. *J Neurosci Res.* 2001;64: 341–347.
1225 doi:10.1002/jnr.1084
- 1226 106. Agis-Balboa RC, Fischer A. Generating new neurons to circumvent your fears: The
1227 role of IGF signaling. *Cellular and Molecular Life Sciences. Cell Mol Life Sci*; 2014. pp.
1228 21–42. doi:10.1007/s00018-013-1316-2
- 1229 107. Chaker Z, Aïd S, Berry H, Holzenberger M. Suppression of IGF-I signals in neural
1230 stem cells enhances neurogenesis and olfactory function during aging. *Aging Cell.*
1231 2015;14: 847–856. doi:10.1111/acer.12365
- 1232 108. Kuwabara T, Kagalwala MN, Onuma Y, Ito Y, Warashina M, Terashima K, et al.
1233 Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the
1234 olfactory bulb. *EMBO Mol Med.* 2011;3: 742–754. doi:10.1002/emmm.201100177
- 1235 109. Van Brocklyn JR, Williams JB. The control of the balance between ceramide and
1236 sphingosine-1-phosphate by sphingosine kinase: Oxidative stress and the seesaw of
1237 cell survival and death. *Comparative Biochemistry and Physiology - B Biochemistry
1238 and Molecular Biology.* Elsevier Inc.; 2012. pp. 26–36. doi:10.1016/j.cbpb.2012.05.006
- 1239 110. Ghasemi R, Dargahi L, Ahmadiani A. Integrated sphingosine-1 phosphate signaling in
1240 the central nervous system: From physiological equilibrium to pathological damage.
1241 *Pharmacological Research.* Academic Press; 2016. pp. 156–164.
1242 doi:10.1016/j.phrs.2015.11.006
- 1243 111. Karunakaran I, van Echten-Deckert G. Sphingosine 1-phosphate – A double edged
1244 sword in the brain. *Biochimica et Biophysica Acta - Biomembranes.* Elsevier B.V.;
1245 2017. pp. 1573–1582. doi:10.1016/j.bbamem.2017.03.008
- 1246 112. Kanno T, Nishizaki T, Proia RL, Kajimoto T, Jahangeer S, Okada T, et al. Regulation
1247 of synaptic strength by sphingosine 1-phosphate in the hippocampus. *Neuroscience.*
1248 2010;171: 973–980. doi:10.1016/j.neuroscience.2010.10.021
- 1249 113. Martin JL, Lin MZ, McGowan EM, Baxter RC. Potentiation of growth factor signaling by
1250 insulin-like growth factor-binding protein-3 in breast epithelial cells requires
1251 sphingosine kinase activity. *J Biol Chem.* 2009;284: 25542–25552.
1252 doi:10.1074/jbc.M109.007120
- 1253 114. Jęsko H, Stępień A, Lukiw WJ, Strosznajder RP. The Cross-Talk Between
1254 Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and
1255 Neurodegeneration. *Molecular Neurobiology.* Humana Press Inc.; 2019. pp. 3501–
1256 3521. doi:10.1007/s12035-018-1286-3
- 1257 115. Paliouras GN, Hamilton LK, Aumont A, Joppé SE, Barnabé-Heider F, Fernandes KJL.
1258 Mammalian target of rapamycin signaling is a key regulator of the transit-amplifying
1259 progenitor pool in the adult and aging forebrain. *J Neurosci.* 2012;32: 15012–15026.
1260 doi:10.1523/JNEUROSCI.2248-12.2012
- 1261 116. Sandberg R, Larsson O. Improved precision and accuracy for microarrays using
1262 updated probe set definitions. *BMC Bioinformatics.* 2007;8. doi:10.1186/1471-2105-8-
1263 48
- 1264 117. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al.
1265 Exploration, normalization, and summaries of high density oligonucleotide array probe
1266 level data. *Biostatistics.* 2003;4: 249–264. doi:10.1093/biostatistics/4.2.249
- 1267 118. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy - Analysis of Affymetrix GeneChip
1268 data at the probe level. *Bioinformatics.* 2004;20: 307–315.
1269 doi:10.1093/bioinformatics/btg405
- 1270 119. Mhyre TR, Chesler EJ, Thiruchelvam M, Lungu C, Cory-Slechta DA, Fry JD, et al.
1271 Heritability, correlations and in silico mapping of locomotor behavior and
1272 neurochemistry in inbred strains of mice. *Genes, Brain Behav.* 2005;4: 209–228.
1273 doi:10.1111/j.1601-183X.2004.00102.x
- 1274 120. Bates D, Mächler M, Bolker BM, Walker SC. Fitting linear mixed-effects models using
1275 lme4. *J Stat Softw.* 2015;67: 1–48. doi:10.18637/jss.v067.i01
- 1276 121. Saar K, Beck A, Bihoreau MT, Birney E, Brocklebank D, Chen Y, et al. SNP and
1277 haplotype mapping for genetic analysis in the rat. *Nat Genet.* 2008;40: 560–566.

- 1278 doi:10.1038/ng.124
- 1279 122. Wang J, Williams RW, Manly KF. WebQTL: Web-Based Complex Trait Analysis.
- 1280 Neuroinformatics. Neuroinformatics; 2003. pp. 299–308. doi:10.1385/NI:1:4:299
- 1281 123. Abiola O, Angel JM, Avner P, Bachmanov AA, Belknap JK, Bennett B, et al. The
- 1282 nature and identification of quantitative trait loci: A community's view. Nature Reviews
- 1283 Genetics. Nat Rev Genet; 2003. pp. 911–916. doi:10.1038/nrg1206
- 1284 124. Lander E, Kruglyak L. Genetic dissection of complex traits: Guidelines for interpreting
- 1285 and reporting linkage results. Nat Genet. 1995;11: 241–247. doi:10.1038/ng1195-241
- 1286 125. Broman KW, Sen S. A guide to QTL mapping with R/qtl. 2009.
- 1287 126. Langfelder P, Horvath S. WGCNA: An R package for weighted correlation network
- 1288 analysis. BMC Bioinformatics. 2008;9: 559. doi:10.1186/1471-2105-9-559
- 1289 127. Smith JR, Hayman GT, Wang SJ, Laudederkind SJF, Hoffman MJ, Kaldunski ML, et al.
- 1290 The Year of the Rat: The Rat Genome Database at 20: A multi-species
- 1291 knowledgebase and analysis platform. Nucleic Acids Res. 2020;48: D731–D742.
- 1292 doi:10.1093/nar/gkz1041
- 1293 128. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al.
- 1294 Primer3-new capabilities and interfaces. Nucleic Acids Res. 2012;40: e115.
- 1295 doi:10.1093/nar/gks596
- 1296 129. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq
- 1297 quantification. Nat Biotechnol. 2016;34: 525–527. doi:10.1038/nbt.3519
- 1298 130. Cunningham F, Achuthan P, Akanni W, Allen J, Amode MR, Armean IM, et al.
- 1299 Ensembl 2019. Nucleic Acids Res. 2019;47: D745–D751. doi:10.1093/nar/gky1113
- 1300 131. Pimentel H, Bray NL, Puente S, Melsted P, Pachter L. Differential analysis of RNA-seq
- 1301 incorporating quantification uncertainty. Nat Methods. 2017;14: 687–690.
- 1302 doi:10.1038/nmeth.4324
- 1303 132. Krämer A, Green J, Pollard J, Tugendreich S. Causal analysis approaches in ingenuity
- 1304 pathway analysis. Bioinformatics. 2014;30: 523–530.
- 1305 doi:10.1093/bioinformatics/btt703
- 1306 133. R Core Team. R: A language and environment for statistical computing. R Foundation
- 1307 for Statistical Computing, Vienna, Austria. 2002. Available: <https://www.r-project.org/>.
- 1308 134. Fox J. An R Companion to Applied Regression. Third. Sage, Thousand Oaks CA;
- 1309 2019. Available: <https://socialsciences.mcmaster.ca/jfox/Books/Companion/>
- 1310 135. Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models.
- 1311 Biometrical Journal. Biom J; 2008. pp. 346–363. doi:10.1002/bimj.200810425
- 1312 136. Wickham H. ggplot2 - Elegant Graphics for Data Analysis. Springer; 2016. Available:
- 1313 <https://www.springer.com/de/book/9780387981413>
- 1314

1315 **Supporting Tables**

1316 **Table S1. Quantitative RT-PCR analysis of *Tti2* mRNA expression in BN and SHR rats.**

Tissue	$\Delta\Delta\text{CT}$ (SHR – BN)	<i>t</i>	df	<i>p</i> -value
Adrenal gland	-0.39 ± 0.13	1.84	9	0.099
Perirenal fat	1.15 ± 0.13	-4.83	8	0.0013
Hippocampus	-0.88 ± 0.1	3.5	8	0.0081
Kidney	-1.14 ± 0.12	5.31	8	0.00072
Liver	-0.85 ± 0.08	2.77	9	0.022
Soleus muscle	-1.49 ± 0.15	7.34	8	8.10E-05
Pancreas	-1.15 ± 0.11	2.49	8	0.037

1317

1318 Expression values were normalised to the mean expression of *Tti2* in BN. Note that lower
 1319 cycle of threshold ($\Delta\Delta\text{CT}$) values indicate higher relative expression of a gene. Data is shown
 1320 as means ± standard error of the mean; *t*, Student's *t*-test statistic; df, degrees of freedom.

1321

1322 **Table S2. Non-synonymous amino acid substitutions in the SHR *Tti2* coding**

1323 **sequence.**

Position	Conservation Score	Reference	SHR	Reference Amino Acid	Variant Amino Acid	Amino Acid Coordinate	Polypeptide Prediction	SIFT Prediction
64399852	0.909	T	G	E	D	247	benign	0.15
64401758	0.277	C	T	A	T	205	benign	0.71
64401779	0.567	T	C	K	E	198	benign	1
64402213	0.005	C	T	R	K	53	benign	0.9
64402331	0.001	A	G	C	R	14	benign	0.2
64402360	0	C	T	G	D	4	benign	1

1324

1325 Genomic sequence of SHR rats between positions 62.1 and 66.3 Mb on chromosome 16,
 1326 which cover neurogenesis-glucose QTL, was scanned for non-synonymous amino-acid
 1327 substitutions compared to reference genome using Variant Visualiser in Rat Genome
 1328 Database. Within this interval, missense mutations were present only in the *Tti2* gene.

1329 Conservation score ranges from 1 (highly conserved) to 0 (not conserved). SIFT score
1330 ranges from 0 (damaging) to 1 (non-damaging). Positions are according to Rnor_5.0 genome
1331 assembly.

1332 **Table S3. RNAseq confirmed reduction of *Tti2* mRNA expression in SHR-*Tti2*^{+/-} rats**
1333 **compared to wild type SHR littermates.**

Tissue	beta	se	<i>p</i> value	<i>q</i> value
Hippocampus	-0.54	0.07	1.40E-15	2.8E-11
Liver	-0.53	0.08	7.7E-11	1.8E-07
Fat	-0.46	0.07	1.7E-11	3.5E-07
Muscle	-0.63	0.06	3.70E-22	6.7E-18

1334

1335 **Supporting Figure Captions**

1336 **Fig. S1. Metabolic phenotyping of three-months old heterozygous SHR-*Tti2*^{+/-} rats and**
1337 **wild type SHR- *Tti2*^{+/+} littermates (denoted as SHR).**

1338 Details of statistical analysis are in Table 2. Abbreviations: BAT, brown adipose tissue; GSH,
1339 glutathione; HDL, high-density lipoprotein; TG, triglycerides.

1340 **Fig. S2. Top canonical pathways enriched among differentially expressed genes**
1341 **between SHR-*Tti2*^{+/-} rats and wild type SHR littermates.**

1342 Analysis was performed with Ingenuity pathway analysis (IPA), which, in addition to
1343 calculating enrichment, predicts activation (positive Z-score, red) or inhibition (negative Z-
1344 score, blue) of molecular pathways from the direction and magnitude of expression changes
1345 using curated database. Grey bars depict enriched pathways for which activation status
1346 could not be predicted. Vertical green dashed line indicates *p* value threshold of 0.05.

1347 **Fig. S3. Predicted regulator networks effects involved in glucose homeostasis in livers**
1348 **of SHR-*Tti2*^{+/-} rats**

1349 Differentially expressed genes in livers of SHR-*Tti2*^{+/-} rats and wild type SHR littermates were
1350 analysed using IPA. Up- (magenta) and downregulated genes (green; middle tier) connect
1351 the potential upstream regulators (upper tier) to downstream outcomes (bottom tier). Edges
1352 represent relationships derived from curated databases.

1353 **Fig. S4. Frequencies of single- and multi-tissue human *TTI2* eQTL.**

1354 821 genomic variants underlying 2177 eQTL ($p < 1e-4$) extracted from eQTL EBI catalogue
1355 (<https://www.ebi.ac.uk/eql/>) were clustered according to the number of distinct tissues or cell
1356 types in which eQTL were detected. Multiple eQTL from different data sets derived from the
1357 same cell or tissue type were scored as a single-tissue eQTL.

1358 **Supporting Information Files**

1359 **File S1. Ingenuity canonical pathways.**

1360 IPA canonical pathways enriched in differentially expressed genes in SHR-*Tti2*^{+/-} vs. wild type
1361 SHR rats in the hippocampus, liver, muscle and perirenal adipose tissue.

1362 **File S2. Ingenuity upstream regulators.**

1363 Affected upstream regulators predicted by IPA from differentially expressed genes in SHR-
1364 *Tti2*^{+/-} vs. wild type SHR rats in the hippocampus, liver, muscle and perirenal adipose tissue.
1365 Activation Z-score is deduced from the direction and magnitude of the gene expression
1366 changes.

1367 **File S3. Ingenuity downstream functions and diseases.**

1368 Functions enriched among differentially expressed genes in SHR-*Tti2*^{+/-} vs. wild type SHR
1369 rats in the hippocampus, liver, muscle and perirenal adipose tissue. IPA deduces the
1370 activation Z-scores from the direction and magnitude of the gene expression changes.

1371 **File S4. Human *TTI2* eQTL.**

1372 Human eQTL catalogue (<https://www.ebi.ac.uk/eql/>) was queried for variants associated with
1373 changes in the *TTI2* mRNA expression. Significant eQTL were defined by p value < 1e-4.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5